

University of Dundee

Yeast Svf1 binds ceramides and contributes to sphingolipid metabolism at the ER cis-Golgi interface

Limar, Sergej; Körner, Carolin; Martínez-Montañés, Fernando; Stancheva, Viktoriya; Wolf, Verena; Walter, Stefan

Published in:
Journal of Cell Biology

DOI:
[10.1083/jcb.202109162](https://doi.org/10.1083/jcb.202109162)

Publication date:
2023

Licence:
CC BY-NC-SA

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Limar, S., Körner, C., Martínez-Montañés, F., Stancheva, V., Wolf, V., Walter, S., Miller, E., Ejsing, C., Galassi, V., & Fröhlich, F. (2023). Yeast Svf1 binds ceramides and contributes to sphingolipid metabolism at the ER cis-Golgi interface. *Journal of Cell Biology*, 222(5), Article e202109162. <https://doi.org/10.1083/jcb.202109162>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

ARTICLE

Yeast Svf1 binds ceramides and contributes to sphingolipid metabolism at the ER cis-Golgi interface

Sergej Limar¹, Carolin Körner¹, Fernando Martínez-Montañés², Viktoriya G. Stancheva³, Verena N. Wolf¹, Stefan Walter⁴, Elizabeth A. Miller³, Christer S. Ejsing^{2,5}, Vanesa Viviana Galassi^{6,7}, and Florian Fröhlich^{1,4}

Ceramides are essential precursors of complex sphingolipids and act as potent signaling molecules. Ceramides are synthesized in the endoplasmic reticulum (ER) and receive their head-groups in the Golgi apparatus, yielding complex sphingolipids (SPs). Transport of ceramides between the ER and the Golgi is executed by the essential ceramide transport protein (CERT) in mammalian cells. However, yeast cells lack a CERT homolog, and the mechanism of ER to Golgi ceramide transport remains largely elusive. Here, we identified a role for yeast Svf1 in ceramide transport between the ER and the Golgi. Svf1 is dynamically targeted to membranes via an N-terminal amphipathic helix (AH). Svf1 binds ceramide via a hydrophobic binding pocket that is located in between two lipocalin domains. We showed that Svf1 membrane-targeting is important to maintain flux of ceramides into complex SPs. Together, our results show that Svf1 is a ceramide binding protein that contributes to sphingolipid metabolism at Golgi compartments.

Introduction

Lipid intermediates, such as ceramide, are toxic when they accumulate in cellular membranes. Ceramides affect membrane structure and, additionally, function as signaling molecules promoting cell death. Therefore, it is not surprising that elevated ceramide levels have been linked to diseases, including neurodegenerative disorders, diabetes, and cardiovascular diseases (Alessenko and Albi, 2020; Holland et al., 2007; Pickersgill et al., 2007). This is not unique to highly specialized cells, as also in the model organism *Saccharomyces cerevisiae*, elevated ceramide levels have been associated with cell death (Eisenberg and Büttner, 2014). Ceramide in particular regulates various phosphatases (e.g., of the PP2A family) and kinases (including AKT, PKC, and MAP kinases) leading to decreased cellular proliferation (Bourbon et al., 2002; Teixeira et al., 2015; Dobrowsky et al., 1993).

The enzymes required for the biosynthesis of ceramide and all other SP species are known. Serine palmitoyl transferase (SPT) catalyzes the condensation of serine and palmitoyl-CoA to yield 3-keto-dihydrosphingosine. This short-lived intermediate is directly processed to dihydrosphingosine (DHS) and phytosphingosine (PHS). In a second metabolic pathway, the very long-chain fatty acids (VLCFAs) are synthesized through

elongation of palmitoyl-CoA to 24 or 26 carbon chains (Dickson and Lester, 1999). A long-chain base (LCB) and a VLCFA are amide-linked to form ceramide. At the Golgi apparatus, ceramides receive various head groups to yield the complex SPs, such as sphingomyelin in mammalian cells or inositol-containing ceramides in yeast. Complex SPs are secreted from the Golgi to reach the plasma membrane by vesicular transport (Klemm et al., 2009). In addition, ceramides are also generated by the degradation of complex sphingolipids (SPs). In mammalian cells, this process is catalyzed by, for example, sphingomyelinases and glucosyl- β -glycosidases (Andrieu-Abadie and Levade, 2002; Sarmientos et al., 1986). In yeast, a single enzyme, Isc1, has been reported to hydrolyze complex SPs (Sawai et al., 2000). There is evidence that cells convert excess ceramides into other lipids to prevent toxicity. For example, the sphingomyelin synthase-related protein (SMSr) generates ceramide phosphoethanolamine from ceramide (Vacaru et al., 2009). Data from yeast and mammals suggest that ceramides can be acylated to generate acyl-ceramides that are supposedly stored in lipid droplets (Senkal et al., 2017; Voynova et al., 2012).

Besides their further processing, SP biosynthesis is highly regulated. When SP levels at the plasma membrane are low, the

¹Department of Biology/Chemistry Bioanalytical Chemistry Section, Osnabrück University, Osnabrück, Germany; ²Department of Biochemistry and Molecular Biology Villum Center for Bioanalytical Sciences, University of Southern Denmark, Odense, Denmark; ³MRC Laboratory of Molecular Biology, Cambridge, UK; ⁴Osnabrück University Center of Cellular Nanoanalytical Osnabrück (CellNanos), Osnabrück, Germany; ⁵Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany; ⁶Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Cuyo, Mendoza, Argentina; ⁷Instituto Interdisciplinario de Ciencias Básicas (ICB), Universidad Nacional de Cuyo, CONICET, Mendoza, Argentina.

Correspondence to Florian Fröhlich: florian.froehlich@uos.de.

© 2023 Limar et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).

target of rapamycin complex 2 (TORC2) is activated and phosphorylates the yeast SGK1 homologue Ypk1. This leads to phosphorylation of the Orm proteins, negative regulators of the serine palmitoyltransferase, resulting in release of the inhibition and increased SP biosynthesis (Roelants et al., 2011). It was recently shown that upon phosphorylation, Orm2 is transported to the Golgi apparatus and degraded via the proteasome (Schmidt et al., 2019). Because of its resemblance to the ERAD pathway, this pathway has been termed Endosome/Golgi associated degradation (EGAD), and Orm2 has become the model substrate of this pathway. Moreover, recent work from our laboratory suggests that another level of regulation involves regulated uptake and direct shunting of serine into the SP metabolic pathway (Esch et al., 2020). Other mechanisms controlling SP homeostasis include the regulation of VLCFA synthesis (Olson et al., 2015) and the regulation of ceramide biosynthesis by the Ypk kinases (Muir et al., 2014). In addition, the lysosomal TOR complex has been suggested to regulate ceramide biosynthesis via control of ORM phosphorylation (Shimobayashi et al., 2013).

Although we are beginning to understand how SP metabolism is regulated, very little is known about the transfer of SPs between membranes. Other lipid classes are frequently transported between organelles via lipid transport proteins (Wong et al., 2018). Examples for this mechanism include the Oxysterol-binding protein (OSBP)-related proteins that transport both sterols and glycerophospholipids in exchange for phosphatidyl-inositol-4-phosphate (PI4P; Moser von Filseck et al., 2015; Maeda et al., 2013; Mesmin et al., 2013; Antonny et al., 2018). However, very little is known about SP transfer proteins, especially in yeast cells. In mammalian cells, ceramide is transported to the Golgi by CERT (Hanada et al., 2003). CERT binds to VAMP-associated proteins (VAPs) via its FFAT (two phenylalanines in acidic tract) motif at the ER and to PI4P at the Golgi apparatus via its pleckstrin homology (PH) domain, thereby tethering the two organelles. Ceramides are transported by a StAR-related lipid transfer (START) domain (Kumagai et al., 2019). A similar mechanism probably occurs in yeast cells, but the corresponding ceramide transfer protein has yet to be identified. One candidate protein is the Nuclear Vacuolar Junction protein 2 (Nvj2), which has been shown to be important for ceramide transfer between the ER and the Golgi apparatus (Liu et al., 2017). However, this process occurs only in cells that have high levels of ER stress. In addition, yeast tricalbins have also been implicated in ceramide transport between ER and Golgi (Ikeda et al., 2020). Ceramides in yeast cells are also transported by vesicular trafficking (Funato and Riezman, 2001). The molecular mechanism for this process remains largely elusive. The OSBP homologs Osh2, Osh3, and Osh4 together have been implicated in this process (Kajiwara et al., 2014). However, a direct role of the Osh2, Osh3, and Osh4 proteins in sorting ceramides into COP-II vesicles appears to be unlikely since their function in lipid transport has been described (Moser von Filseck et al., 2015; Mesmin et al., 2013; Maeda et al., 2013; Encinar Del Dedo et al., 2021). In summary, a complete picture of yeast ceramide transport is still lacking.

Here, we describe another putative ceramide transfer protein in yeast, survival factor 1 (Svf1). Using chemical genetic data

mining, we identified overlapping functions of Svfl with Nvj2 and the proteins Osh1 and Osh3. We used lipidomics and flux analysis to show that *SVF1* mutant cells have decreased levels of complex SPs with a concomitant increase in ceramides, which is independent of the COP-II mediated transport machinery. Our analysis reveals that Svfl is localized at the cis-Golgi apparatus and the cytoplasm. We identified an amphipathic helix (AH) at the N-terminus of Svfl that is required for Golgi targeting. Using molecular docking studies and targeted lipidomics, we show that Svfl harbors a hydrophobic binding pocket for ceramide that is located between its two lipocalin-like domains. Ceramide binding is abolished upon mutating two histidines in a potential cap region covering the hydrophobic pocket, which also leads to the loss of Svfl localization at the cis-Golgi. Together, our data suggest that Svfl is a ceramide binding protein that is involved in SP biosynthesis at the cis-Golgi most likely by transporting ceramide from the ER to the Golgi apparatus.

Results

SVF1 genetically interacts with genes involved in ceramide transport

Ceramide transport in yeast occurs by vesicular transport as well as non-vesicular transport mediated by Nvj2 (Fig. 1, a and b). Since Nvj2-mediated ceramide transport occurs only under conditions of high ER stress, we suspected that another protein might be functioning in ceramide transport. To identify this protein, we first analyzed high-throughput chemical genetics datasets (Hillenmeyer et al., 2008). Besides an effect of a gene knockout on drug resistance or sensitivity, these datasets also contain information on the similarity of genetic profiles. Highly similar profiles often indicate similar functions of genes in the cell. Our analysis revealed that the yeast gene *SVF1* shows the highest correlation with *NVJ2*, a dubious open reading frame overlapping with *NVJ2* (*YPR092W*) and two *OSH* (*OSH1* and *OSH3*) genes, suggesting a potential role in ceramide transport within the cell (Fig. 1 c). *SVF1* has been linked previously to SP homeostasis by interacting with the DHS hydroxylase *SUR2*. In addition, an *osh2Δosh3Δosh4Δ* strain has been used previously to identify the role of Nvj2 in ceramide transport (Liu et al., 2017). Tetrad analysis revealed that the additional deletion of *SVF1* in an *osh2Δosh3Δosh4Δ* background aggravated the growth defect of the triple mutant. Similarly, the additional deletion of *NVJ2* also aggravates the growth defect of the *osh2Δosh3Δosh4Δ*, suggesting that Svfl might be another protein functioning in ceramide transport (Fig. 1 d; quantification in Fig. S1, a and b). Generating the quintuple mutant of *OSH2*, *OSH3*, *OSH4*, *NVJ2*, and *SVF1* yields the strongest growth defect, but the cells are still viable, suggesting that some ceramides are still transported (Fig. 1 d). Two other candidate genes that could be involved in ceramide transport are the Svfl-like genes *YLR225C* and *YDR222W*. To test whether these genes have overlapping functions with *SVF1*, we utilized a synthetic interaction between *SVF1* and *SUR2*, which also serves to further highlight its role in SP metabolism. Loss of *SVF1* was previously shown to have a strong negative genetic interaction with deletion of the sphinganine-C4 hydroxylase *SUR2* (Fig. S1 c; Brace et al., 2007). Deletion of neither *YLR225C*

nor *YDR222W* alone, nor in combination with *SVF1*, showed an aggravated synthetic interaction with *SUR2*, suggesting neither gene is a functional homolog of *SVF1* (Fig. S1 d).

To further investigate the role of *Svf1* in SP metabolism and ceramide transport, we spotted WT, *svf1Δ*, *nvj2Δ*, and *svf1Δnvj2Δ* cells on control plates and plates containing the SP biosynthesis inhibitor myriocin. While both single mutants grow similar to a WT strain, the double deletion of *SVF1* and *NVJ2* is sensitive to chemical inhibition of SP biosynthesis, further supporting a role in SP homeostasis (Fig. 1 e).

Svf1 localizes to the cis-Golgi apparatus

To start dissecting the role of *Svf1* in SP metabolism, we first tagged *Svf1* at its C-terminus with GFP, which revealed a punctuate localization with additional cytosolic signal (Fig. 2 a). To reveal the identity of the punctuate structures, we systematically co-localized *Svf1*-GFP with other organelles in the cell. *Svf1* co-localizes with the cis-Golgi apparatus, marked with *Mnn9*-mKate, but not with the late Golgi (*Sec7*-mKate), endosomes (*Vps4*-3xmCherry), or the endoplasmic reticulum marked with *dsRed*-HDEL (Fig. 2 a). To further confirm the co-localization of *Svf1*-GFP and *Mnn9*-mCherry, we analyzed the co-localization of both proteins over time. This analysis revealed that *Svf1*-GFP localizes dynamically to *Mnn9*-mKate positive structures (Fig. 2 b and Video 1). Together, our results demonstrate that *Svf1* localizes at the cis-Golgi apparatus as well as in the cytoplasm (Fig. 2 c). This phenotype suggests an interaction of *Svf1* with either a membrane protein at the cis-Golgi or directly with the membrane. In contrast to a C-terminal tagged version, an N-terminal GFP-tagged *Svf1* was not sufficient to rescue the synthetic interaction with *SUR2* (Fig. S2), suggesting an important role for the *Svf1* N-terminus.

An N-terminal amphipathic helix is necessary for Svf1 targeting to the cis-Golgi

To identify a potential targeting motif in the N-terminus of *Svf1*, we performed a HeliQuest analysis (Gautier et al., 2008) This revealed a putative AH within the first 18 amino acids (Fig. 3 a). To test whether the amphipathic nature of the N-terminal helix of *Svf1* is necessary for targeting to the cis-Golgi, we mutated the hydrophobic valine residue in position 12 to a negatively charged aspartic acid, largely destroying the hydrophobic moment (Fig. 3, b and c). Expression of *Svf1*-GFP from an integrative plasmid under control of the endogenous promoter in a *svf1Δ* strain confirmed the dual localization of *Svf1* to the cis-Golgi marked with *Mnn9*-mCherry and the cytoplasm (Fig. 3 d, upper panel). In contrast, the expression of the *Svf1_{V12D}*-GFP mutant showed only cytosolic GFP signal, strongly supporting the model of the N-terminal AH in *Svf1* driving membrane recruitment (Fig. 3 d, lower panels). We noted that expression of *Svf1*-GFP from an integrative plasmid under its endogenous promoter resulted in some overexpression of the protein as detected by microscopy as well as on Western blots (Fig. S3 a). Although we do not have an explanation for this phenotype, we continued our analyses with the appropriate controls. To confirm our results biochemically, we pelleted membranes from *Svf1*-GFP and *Svf1_{V12D}*-GFP cells and analyzed pellet fractions and supernatant




Figure 1. **SVF1 interacts genetically with yeast genes involved in ceramide transport.** (a and b) A model for vesicular and non-vesicular ceramide transport in yeast under normal growth and ER stress conditions (b). (c) Histogram of correlation coefficients based on the genetic profiles of yeast mutants in chemical genetic screens. Data was extracted from Hillenmeyer et al. (2008). (d) Tetrad analysis of *svf1Δosh3Δosh4Δ* (green, yellow, and red, respectively) mutants crossed with *nvj2Δosh2Δ* (orange and blue, respectively). (e) Serial dilutions of WT, *svf1Δ*, *nvj2Δ*, and *svf1Δnvj2Δ* on YPD plates (control) and YPD plates containing 0.5 μM myriocin.

fractions by Western blot. While *Svf1*-GFP was present in both fractions, we were only able to detect *Svf1_{V12D}*-GFP in the supernatant fraction, confirming that its inability to interact with




Figure 2. **Svf1 dynamically colocalizes with the cis-Golgi.** (a) Svf1-GFP was expressed in cells expressing either Mnn9-mKate (cis-Golgi), Sec7-mKate (trans-Golgi), Vps4-3xmCherry (endosome) or HDEL-dsRed (ER). Line scans (right) of the indicated regions of Svf1-GFP (green) and the respective co-expressed organelle markers (magenta). Scale bar = 5 μm. Scale bar inlays = 1 μm. (b) Co-localization of Svf1-GFP and 3xmCherry tagged Mnn9 imaged every 0.9 s over a total time of 9.9 s to confirm the localization to the cis-Golgi. Scale bar = 5 μm. (c) A model of the two interchanging states, cytosolic and membrane bound, of Svf1 in the cell.

membranes (Fig. 3 e). Next, we asked whether localization of Svf1 to the cis-Golgi is required for its function. To assess this, we dissected *svf1Δsur2Δ* cells expressing either Svf1-GFP or *Svf1^{V12D}-GFP* from a plasmid. While the expression of Svf1-GFP was sufficient to rescue the synthetic phenotype of *SVF1* and *SUR2* double deletions (Fig. 3 f), the strain harboring *Svf1^{V12D}-GFP* phenocopied the *svf1Δsur2Δ* strain (Fig. 3 g). These results show that the targeting of Svf1 via its N-terminal AH is necessary for its function (Fig. 3 h). The two proteins annotated as Svf1 homologs do not possess N-terminal AHs which might also explain why they do not function in SP homeostasis (Fig. S1 c).

Another cis-Golgi localized protein, Grh1, has also been shown to target the cis-Golgi via an AH (Behnia et al., 2007). In addition, Grh1 requires N-terminal acetylation for its targeting to the cis-Golgi. We thus speculated that Svf1 also requires N-terminal acetylation for its targeting. Recently, a targeting motif for N-terminal acetylation by the yeast NatC complex has been identified (Grunwald et al., 2020). According to this prediction, Svf1 is also a target of the NatC complex. To test our hypothesis, we mutated the leucine residue following the first

amino acid to glutamic acid (L2E). This barely affects the hydrophobic moment of the AH but should abolish N-terminal acetylation by NatC (Fig. S3 b). In line with this prediction, *Svf1^{L2E}-GFP* does not rescue the growth of a *svf1Δsur2Δ* double deletion (Fig. 3 i). In addition, fractionation analysis revealed that Svf1-GFP becomes largely cytosolic in cells lacking *MAK3*, the catalytic subunit of NatC, compared to WT cells, suggesting that N-terminal acetylation is indeed necessary for membrane targeting of Svf1 (Fig. 3 j). Furthermore, mass spectrometric analysis confirmed the N-terminal acetylation of Svf1 (Fig. S4 a). Interestingly, we always observed both a cytosolic fraction as well as a membrane bound fraction of Svf1. The dual localization can be explained by two adjacent glycine residues (G7 and G8) in the AH of Svf1. Glycine is a common feature of AHs that is thought to prevent their folding in the absence of a membrane surface (Drin and Antonny, 2010; Cornell and Taneva, 2006). We tested whether we can increase the Svf1 membrane interaction by mutating both glycine residues to alanines (G7A/G8A), which are preferable for helix folding (Pace and Scholtz, 1998). This mutation left the hydrophobic moment of the AH largely




Figure 3. **Svfl possesses an N-terminal amphipathic helix important for the targeting and function of the protein.** (a and b) Helical wheel representation of the first 18 amino acids with the hydrophobic amino acids shown in yellow and the hydrophobic moment shown by the arrow and expressed in μH above the arrow for the WT sequence and (b) the V12D mutant with the exchange of the hydrophobic valine to the charged aspartate (red). (c) Graphical representation of the full-length protein (WT, left; V12D mutant, right). Shown are the AH (yellow, 1–18 aa), the rest of Svfl (orange, 19–481 aa) and the C-terminal GFP tag (green). (d) Co-localization of GFP tagged Svfl expressed from a plasmid under control of the endogenous promoter with mCherry tagged Mnn9 for the WT (upper panel) and the V12D mutant (lower panel). Scale bar = 5 μm . Scale bar inlays = 1 μm . (e) Samples from the membrane fractionation according to 50 μg protein concentration were analyzed by Western blot. The separation of the cell lysate (Input, I) into pellet (P) and supernatant (S) fractions

shows the Svf1 localization either bound to membranes (P) or cytosolic (S) detected by an α -GFP antibody. The antibodies α -Pgl1 and α -Sec61 were used as loading controls for the cytosol and membrane fractions, respectively. **(f)** Tetrad analysis of the *svf1 Δ pl.Svf1-GFP* (blue and green, respectively) mutants crossed with *sur2 Δ* (red). **(g)** Tetrad analysis of the *svf1 Δ pl.Svf1_{V12D}-GFP* (blue and green, respectively) mutants crossed with *sur2 Δ* (red). **(h)** A model of Svf1 with the folded (bound Svf1) and unfolded (cyt. Svf1) N-terminal AH. **(i)** Tetrad analysis of the *svf1 Δ pl.Svf1_{L2E}-GFP* (blue and green, respectively) mutants crossed with *sur2 Δ* (red). **(j)** Western blot analysis of Svf1-GFP in WT and *mak3 Δ* mutant as described in e. **(k and l)** Helical wheel representation of the WT AH (k) and the *G7A/G8A* mutant AH (l) described as in Fig. 3 a shows no impact by the exchanges of glycines to alanines at the positions 7 and 8 on the hydrophobic moment of the AHs. **(m)** Co-localization of GFP tagged Svf1 expressed from a plasmid under the control of the endogenous promoter of Svf1 in a *svf1 Δ* background (WT, upper panel; *G7A/G8A* mutant, lower panel), with the organelle markers Mnn9-mKate (cis-Golgi) and Sec63-Halo (ER). Scale bar = 5 μ M. **(n)** Western blot analysis as described in e for Svf1_{WT}-GFP and Svf1_{G7A/G8A}-GFP. Source data are available for this figure: SourceData F3.

unaffected (Fig. 3, k and l). We observed increased co-localization of Svf1_{G7A/G8A}-GFP with the Mnn9-mKate marked cis-Golgi and recruitment of Svf1-GFP to the ER membrane marked with Sec63-Halo (Fig. 3 m). The overall membrane interaction was comparable to WT Svf1 (Fig. 3 n). Together, our results show that Svf1 can dynamically localize between the cytosol and the cis-Golgi apparatus depending on an acetylated N-terminal AH.

The Svf1 N-terminal AH is sufficient for membrane targeting

To further analyze the targeting mechanism of Svf1, we asked whether the AH is also sufficient for targeting. We therefore expressed fusion constructs of the first 18 amino acids of Svf1 and GFP in WT cells under the control of the Svf1 promoter (Fig. 4 a). We were able to detect membrane association of the Svf1₁₋₁₈-GFP construct, but this signal did not co-localize with the cis-Golgi marked by Mnn9-mKate (Fig. 4 b, upper panel). Instead, the AH of Svf1 co-localizes with the ER marked by Sec63 fused to a Halo tag. Expression of the AH containing the V12D mutation only showed a cytosolic signal, as expected from our previous finding (Fig. 4 b, lower panel). To confirm our in vivo results, we fractionated lysates from AH_{WT}-GFP and AH_{V12D}-GFP expressing cells into membrane and supernatant fraction and analyzed the distribution of the constructs by Western blot. This analysis revealed the partial membrane interaction of the WT AH while the V12D AH was only present in the supernatant fraction (Fig. 4 c). Expressing the GFP fused AH harboring, the glycine to alanine mutations also did not result in Golgi targeting of the construct but lead to increased ER membrane association (Fig. 4, d and e; and Fig. S4 b). Together, our results suggest that the Svf1 AH is part of a membrane targeting mechanism of Svf1, but a second mechanism is required for targeting the protein specifically to the cis-Golgi apparatus. As mentioned before, another protein, Grh1 is targeted via an AH to the cis-Golgi apparatus. To test whether the Grh1 AH is sufficient to target Svf1 to the Golgi, we exchanged the Svf1 amphipathic helix by that of Grh1 (Fig. 4 f). While the Grh1 AH has an even stronger hydrophobic moment (Fig. 4 g) than the Svf1 AH, it was not sufficient to target Svf1 to the Golgi apparatus (Fig. 4 h), and the construct was not able to rescue the synthetic phenotype between *SVF1* and *SUR2* (Fig. S4 c). This either suggests that the AH of Svf1 needs to be coordinated itself with other parts of the protein or that Svf1 requires additional interaction partners at the Golgi apparatus for its targeting.

Svf1 acts at the ER Golgi interface

Based on our hypotheses, we tried to identify interaction partners of Svf1. We immuno-purified GFP-tagged Svf1 from cells

metabolically labeled with nonradioactive, stable isotope-labeled ¹³C₆¹⁵N₂ lysine (stable isotope labeling with amino acids in cell culture; Ong et al., 2002). In parallel, we performed a mock purification from control cells labeled with unlabeled lysine. We mixed eluates from both purifications and analyzed them by high-resolution mass spectrometry-based proteomics (Walther and Mann, 2010). Peptides from proteins containing the isotope-labeled lysine are shifted to higher m/z values in the spectra compared with the same peptide from unlabeled protein, allowing quantitation of abundance ratios for each detected peptide and protein from the eluates. This analysis identified a set of multiple co-enriched proteins (Table S1) with many of them being membrane proteins. Amongst them are several enzymes involved in lipid biosynthesis and transport including the VLCFA elongases Elo2, Elo3, and Ifa38 (Fig. 5 a). In addition, we also identified Golgi-resident proteins such as the phosphatidylinositol-4-kinase (PI4P) Pik1 and the mannosyltransferase Mnn5. We also identified proteins of the COP machinery. Amongst them is Sec12, the guanine nucleotide exchange factor (GEF) for Sar1 (Barlowe and Schekman, 1993), the Arf1 GTPase activating protein (GAP) Glo3 (Poon et al., 1999) and Psg1, which has been identified as a component of the Golgi apparatus and COPI vesicles (Geva et al., 2017). These data further support a role for Svf1 at the interface between the ER and the Golgi apparatus, where ceramide transport is focused. It has been previously suggested that the cis-Golgi and ER exit sites contact each other in a “hug-and-kiss” behavior (Kurokawa et al., 2014). We therefore tested whether Svf1 can be co-localized with both, the cis-Golgi (marked with Mnn9-mKate) and ER-exit sites (marked with Sec31-Halo). Our analysis confirmed that ~40% of Svf1 dots co-localized with both Mnn9 positive cis-Golgi and Sec31 containing ER-exit sites (Fig. 5, b and c). In summary, this suggests that Svf1 acts at the interface of the ER and the cis-Golgi apparatus where ceramides are likely transported from one membrane to the other. Since several proteins identified in our interaction studies are part of the COP-II machinery, we next tested whether COP-II-dependent transport is necessary for Svf1 localization to the Golgi apparatus. The dynamic localization of Svf1 to the cis-Golgi is lost when COP-II transport is inhibited. Incubation of cells containing the temperature sensitive allele of Sec12 to the restrictive temperature results in a loss of the puncta of Svf1-GFP most likely reflecting a general loss of the Golgi apparatus when COP-II transport is inhibited (Fig. 5 d). To further investigate whether COP-II is required for Svf1 targeting to the Golgi, we expressed Svf1-GFP in strains harboring temperature-sensitive alleles of either the Sar1 GTPase-activating protein Sec23 or the α -SNAP cochaperone Sec17. We used the




Figure 4. The N-terminal amphipathic helix of Svf1 targets to the ER. (a) Graphical representation of the AH of Svf1 (yellow; WT, left; V12D mutant, middle; G7A/G8A mutant, right) tagged with GFP. (b) Co-localization of the GFP tagged AH expressed from a plasmid under the control of the promoter of Svf1 (WT, upper panel; V12D, lower panel) with the organelle markers Mnn9-mKate (cis-Golgi) and Sec63-Halo (ER). Scale bar = 5 μM. (c) Western

Svf1^{G7A/G8A}-GFP mutant since it showed a stronger affinity for the cis-Golgi apparatus and made the quantifications easier. At the permissive temperature, *Svf1^{G7A/G8A}-GFP* co-localized with the Golgi marker Mnn9-mKate in *sec23^{ts}* cells (Fig. 5 e, upper panels). At the restrictive temperature, *Svf1^{G7A/G8A}-GFP* and Mnn9-mKate were both retained at the ER based on co-localization with Sec63-Halo (Fig. 5 e, upper panels). The increased co-localization can also be seen in the quantification of co-localization of *Svf1^{G7A/G8A}-GFP* with both, Mnn9-mKate and Sec63-Halo (Fig. 5 f). In the *sec17^{ts}* mutant, we already observed reduced levels of the cis-Golgi marked with Mnn9-mKate at the permissive temperature. However, *Svf1^{G7A/G8A}-GFP* co-localization with some of these structures remained (Fig. 5 e, lower panels). At the restrictive temperature both, *Svf1^{G7A/G8A}-GFP* and Mnn9-mKate localized to aberrant structures but the observable Mnn9 signal was very low (Fig. 5 e, lower panels). Together, our results suggest that Svf1 functions at the interface of the cis-Golgi apparatus and the ER. If Svf1 targets the Golgi apparatus via COP-II vesicles or if a general loss of the Golgi apparatus leads to loss of Svf1 localization at these structures cannot be resolved from these experiments.

Svf1 is important for the biosynthesis of complex sphingolipids

To dissect the role of Svf1 at the Golgi, we next focused on its molecular function. Based on our genetic and cell biological experiments, we hypothesized that Svf1 functions in ceramide transport at the ER Golgi interface. To test this, we measured the levels of yeast SPs using LC-MS/MS measurements. We extracted lipids from WT and *svf1Δ* cells as well as a knockout of the sphinganine-C4 hydroxylase *SUR2* as a control. As previously observed, we detected a small but significant decrease in phytosphingosine (PHS) levels in *svf1Δ* cells compared to WT cells (Brace et al., 2007; Fig. 6 a). Deletion of *SUR2* resulted in a

blot analysis of the WT and the V12D AH (WT and *AH_{V12D}*, respectively) fused to GFP. The separation of the cell lysate (Input, I) into pellet (P) and supernatant (S) fractions shows the localization of the GFP tagged AH (WT) and *AH_{V12D}* either bound to membranes (P) or cytosolic (S) detected by an α-GFP antibody. The antibodies α-Pgk1 and α-Sec61 were used as loading controls for the cytosol and membrane fractions, respectively. (d) Co-localization of the GFP tagged AH expressed from a plasmid under the control of the endogenous promoter of Svf1 (WT, upper panel; G7A/G8A, lower panel) with the organelle markers Mnn9-mKate (cis-Golgi) and Sec63-Halo (ER). Scale bar = 5 μM. (e) Western blot analysis of the WT and the G7A/G8A AH (*AH_{WT}* and *AH_{G7A/G8A}*, respectively) fused to GFP. The separation of the cell lysate (Input, I) into pellet (P) and supernatant (S) fractions shows the localization of the GFP tagged *AH_{WT}* and *AH_{G7A/G8A}* either bound to membranes (P) or cytosolic (S) detected by an α-GFP antibody. The antibodies α-Pgk1 and α-Sec61 were used as loading controls for the cytosol and membrane fractions, respectively. (f and g) Helical wheel representation of the 1–18 amino acids of Grh1 as described for Svf1 in Fig. 3 a and (g) represented in the model in purple (right), which were fused to Svf1 (19–481 aa; orange) and a C-terminal GFP tag (green). (h) Co-localization of GFP tagged Svf1 expressed from a plasmid under the control of the endogenous promoter of Svf1 with mKate tagged Mnn9 (upper panel) and the fused protein with the AH of Grh1 (1–18 aa) and Svf1 (19–481 aa) expressed from a plasmid under control of the endogenous promoter of Svf1 with mKate tagged Mnn9 (lower panel). Scale bar = 5 μM. Source data are available for this figure: SourceData F4.




Figure 5. **Svfl acts at the interface of the ER and the cis-Golgi.**

(a) Proteomic analysis of Svfl1-GFP, expressed from a plasmid under the control of the endogenous promoter of Svfl1 in a *svf1Δ* background, and mock treated WT cells is shown. Protein intensities are plotted against heavy/light SILAC ratios. Significant outliers are colored in red ($P < 1^{-11}$), orange ($P < 1^{-4}$), or steel blue ($P < 0.05$), other proteins are shown in light blue. (b) Co-localization of GFP tagged Svfl1 with mKate tagged Mnn9 (cis-Golgi) and Halo tagged Sec31 (ER, ER exit sites). (c) Evaluation of the co-localization of Svfl1 dots ($n = 100$, triplicates) shown in d with either the cis-Golgi (Mnn9), Sec31 (ER, COPII vesicles), or both simultaneously. Scale bar = 5 μ M.

complete shift from LCB 18:0;3 (equivalent of PHS) to LCB 18:0;2 (equivalent of DHS), as expected (Fig. 6 a). However, we also detected increased levels of the major ceramide species (CER 44:0;4) in *svf1Δ* cells compared to WT cells (Fig. 6 b). Consistent with a potential function of Svfl1 in ceramide transport, we detected a decrease in the SP species IPC and MIPC in *svf1Δ* cells compared to WT cells. Moreover, deletion of *SUR2* resulted in a shift from the 44:0;4 species to the 44:0;3 species of IPC and MIPC confirming the reliability of our measurements (Fig. 6 c). Our analysis of the localization of Svfl1 in the background of mutations affecting the COP-II machinery did not allow us to determine whether Svfl1 needs the COP-II machinery for its localization. Prompted by our results that Svfl1 is necessary for the biosynthesis of complex SPs from ceramides, we wanted to dissect the role of Svfl1 in the different pathways required for ceramide transport to the Golgi apparatus. Ceramide transport to the Golgi has been shown to depend on a functional COP-II transport machinery. We first analyzed the levels of complex SPs in a temperature-sensitive mutant of the Sec12 GEF at the restrictive temperature and compared it to WT cells, *svf1Δ* cells and *sec12^{ts}* cells also harboring a deletion of *SVF1*. The levels of complex SPs were depleted in *sec12^{ts}* cells and *svf1Δ* cells (Fig. 6, d–g). This is in line with previously measured reductions in complex SP levels in a *sec12^{ts}* mutant as well as our results obtained for *svf1Δ* cells (Funato and Riezman, 2001). Interestingly, the additional deletion of *SVF1* in a *sec12^{ts}* strain resulted in even stronger depletion of complex SP, suggesting that Svfl1 rather transports ceramides in a parallel pathway to the COP-II vesicular transport pathway. Next, we tested the epistatic effects of the deletion of *OSH2*, *OSH3*, *OSH4*, *NVJ2*, and *SVF1* in the biosynthesis of complex SPs. Deletion of *SVF1* again resulted in the reduction of all IPC and MIPC species determined (Fig. 6, h–k). Deletion of *NVJ2* had a stronger effect on the IPC 44:0;4 and MIPC 44:0;4 species compared to the 44:0;3 species, harboring one less hydroxylation site. The double deletion of *SVF1* and *NVJ2* had an additive effect on the IPC and MIPC 44:0;3 species and was on the same level as the *NVJ2* deletion alone regarding the 44:0;4 species. The similar deletion of *OSH2*, *OSH3*, and *OSH4* was previously suggested to affect ceramide transport by affecting vesicular transport of ceramides (Kajiwara et al., 2014). Similar to these studies, the triple deletion resulted in reduced levels of the major IPC species (Fig. 6, h–k). However, the levels of the more complex SPs, the MIPC species were elevated in the *OSH* triple mutant, suggesting that the mutant does not directly affect ceramide transport but rather leads to an adapted lipid metabolism of the cell. Interestingly, the additional deletion of *SVF1* in the *OSH* triple mutant resulted in the depletion of all analyzed complex SP species, suggesting that Svfl1 is an

(d) Co-localization of GFP tagged Svfl1 with Halo tagged Sec63 (ER marker) in a *sec12^{ts}* background under permissive (24°C, upper panel) and non-permissive (37°C, lower panel) temperature. Scale bar = 5 μ M. (e) Co-localization of GFP tagged Svfl1_{G7A/G8A} with Halo tagged Sec31 (ER marker) and mKate tagged Mnn9 in a *sec23^{ts}* background (upper panels) and in a *sec17^{ts}* background (lower panels) under permissive (24°C) and non-permissive (37°C) temperature. Scale bar = 5 μ M. (f) Quantification of e ($n = 60$, triplicates).

important contributor to cellular ER to Golgi ceramide transport, acting in a parallel pathway to vesicular transport (Fig. 6, h–k). In contrast, the additional deletion of *NVJ2* had no effect on the *OSH2*, *OSH3*, *OSH4* deletion mutant. The quintuple mutant of *OSH2*, *OSH3*, *OSH4*, *NVJ2*, and *SVF1* phenocopied the *OSH SVF1* quadruple mutant, further highlighting *Svf1* also functioning in a parallel pathway to *NVJ2*-dependent ceramide transport (Fig. 6, h–k). In line with our hypothesis, we could not detect an effect for *Svf1* on the content of ceramides on in vitro budded COP-II vesicles (Fig. S5, a–c). We also did not observe any strong phenotype of the *SVF1* deletion on maturation of the GPI anchored protein Gas1 under steady-state conditions (Fig. S5 d), and *Svf1* has not been identified in any screens for genes important for the secretory pathway (Novick et al., 1980).

To further confirm our results, we used multi-pathway flux analysis (Martínez-Montañés et al., 2020), systematically analyzing the incorporation of serine and inositol in SPs, phosphatidylinositol (PI), and phosphatidylserine (PS; Fig. S6 a). We incubated *svf1Δ* cells, *svf1Δ* cells expressing *Svf1*-GFP, *svf1Δ* cells expressing *Svf1_{V12D}*-GFP with ¹³C₃¹⁵N serine and ²H₆-inositol and measured its incorporation into IPC (Esch et al., 2020; Martínez-Montañés et al., 2020). This multi-pathway flux analysis revealed a decreased synthesis rate of the inositol-containing SPs in *svf1Δ* and *Svf1_{V12D}* expressing cells (Fig. 6 l), further supporting a role for *Svf1* in ceramide transport and SP homeostasis. Importantly, we did not observe any detectable differences in the abundance of ¹³C₃¹⁵N serine-containing PS (Fig. 6 m) and ²H₆-inositol containing PI (Fig. 6 n) suggesting, that indeed, ceramide transport is affected by the deletion of *SVF1*, and not, for example the transport of PI to the Golgi apparatus, which is required as a headgroup donor for the synthesis of SPs (Mousley et al., 2008).

According to our data, it remains possible that *Svf1* affects SP metabolism at the Golgi by regulating the activity of *Aur1*, the yeast IPC synthase. We therefore analyzed the localization of *Svf1* compared with *Mnn9* at this cis-Golgi and *Aur1* as a mid-Golgi marker (Fig. S6, b and c). Quantification of the data revealed that almost all *Svf1* spots were positive for *Mnn9*, whereas only half of the *Svf1* structures were also positive for *Aur1*. When we analyzed how many *Svf1* dots were positive for only one of the two markers, *Mnn9* and *Aur1*, we found that half of the *Svf1* dots were co-localized with *Mnn9*, whereas only 5% were exclusively co-localized with *Aur1*. This reinforces our hypothesis that *Svf1* is localized at the cis-Golgi. The co-localization with *Aur1* most likely reflects the dynamics of Golgi maturation in yeast. Furthermore, we did not observe any physical interaction between *Svf1* and *Aur1* in our protein-protein interaction studies, making it unlikely that *Svf1* directly regulates *Aur1*.

Next, we investigated the effect of increased ceramide levels resulting from *SVF1* deletion on yeast physiology. Accumulation of ceramides is toxic to yeast cells (Eisenberg and Büttner, 2014). A pathway for the detoxification of ceramides is the acylation of the free hydroxyl group to yield acyl-ceramide that can be stored in lipid droplets (LDs). This process depends on the diacylglycerol acyltransferases (DGATs) *Lro1* and *Dgal* (Voynova et al., 2012). We spotted WT cells, *svf1Δ*, *nvj2Δ*, *svf1Δnvj2Δ*,

dgalΔlro1Δare1Δare2Δ ($\Delta 4$), $\Delta 4svf1\Delta$, $\Delta 4nvj2\Delta$, and $\Delta 4svf1\Delta nvj2\Delta$ cells on control plates or plates containing the IPC synthase inhibitor Aurobasidin A (AbA) to further increase ceramide toxicity (Fig. 6 o). The deletion of both DGATs *LRO1* and *DGAL* together with the deletion of the acyl-CoA sterol acyltransferase (ACATs) *ARE1* and *ARE2* yields a strain that does not harbor any LDs (Sandager et al., 2002). While *svf1Δ* and $\Delta 4$ cells already showed mild growth defects in the presence of AbA, the combination of both resulted in almost no detectable cell growth (Fig. 6 o). In contrast, combining the *NVJ2* deletion with the $\Delta 4$ mutant showed only mild growth defects similar to the $\Delta 4$ mutant alone (Fig. 6 o). Combining the $\Delta 4$ mutant with both *svf1Δ* and *nvj2Δ* again resulted in a strong growth defect, suggesting that ceramide toxicity is problematic for cells harboring *SVF1* deletions.

Svf1 is a ceramide binding protein

Our results suggest that *Svf1* is a vesicular transport independent ceramide transfer protein at the interface between the ER and the cis-Golgi apparatus. Therefore, we tested whether *Svf1* is capable of binding ceramides. *Svf1* harbors two lipocalin domains that are each made of anti-parallel β -sheets (Weekes et al., 2010). We first used the AlphaFold algorithm (Varadi et al., 2022; Jumper et al., 2021) to predict the structure of *Svf1*. These predictions yield high confidence structures for the two lipocalin domains. Two flexible loops do not yield any structure prediction and the α -helix at the N-terminus of the protein is also predicted with a low confidence score (Fig. 7 a). A different view on the predicted structure highlights the two lipocalin domains in blue and purple that harbor a hydrophobic cleft in each of the lipocalin domains, as well as in between the two domains (Fig. 7 b). To identify potential ceramide binding sites, we performed docking studies of amphiphilic ligands to assess *Svf1* ligand binding sites and lipid loading configurations. Although docking methods failed to reproduce accurately experimental binding energies, their capability to compare affinities at different binding sites and to generate the most probable configurations is well known (Nguyen et al., 2020). Ceramide 18:0; 3/26:0;1 (CER 44:0;4) was assayed in docking experiments with different grids comprising the whole protein, as well as the cavities at each of the β -barrels. All bonds, except for double bonds, were maintained flexible along docking assays. The most probable interaction was found to be at the inter-barrel cleft near an α -helix cap (Fig. 7 c) with binding energies of -6.4 to -5.9 kcal mol⁻¹ for ceramide 44:0;4 for the first most favorable configuration. Both the preferred configurations and the binding energies were found to be independent of the grid size. No stable configuration was produced when forcing the binding to the barrel cavity, while a peripheral binding site to the C-terminus barrel was found near D331, S332, and F466, with a lower binding score of -4.6 and -4.16 kcal mol⁻¹ for ceramide 44:0;4. Together, these simulations render it possible that *Svf1* indeed binds ceramide 44:0;4 in the hydrophobic cleft in between the two lipocalin domains. To directly test whether *Svf1* binds ceramides, we purified FLAG tagged *Svf1*, *Svf1_{V12D}*, and *Svf1_{G7A/G8A}* without detergents from yeast strains overexpressing the proteins under control of the GAL promoter. All proteins were




Figure 6. Lipidomic analysis shows an effect of Svf1 on sphingolipid metabolism. (a and b) Measurement of the different SP intermediates in WT (black), *svf1* Δ (gray), and *sur2* Δ (white) cells shows an alteration of (a) the LCB (LCB 18:0;2 and LCB 18:0;3) levels and (b) the ceramide (CER 44:0;3 and CER 44:0;4)

levels represented in pmol/ μ g protein. **(c)** From the same measurement the levels of the complex SPs IPC (IPC 44:0;3 and IPC 44:0;4) and MIPC (MIPC 44:0;3 and MIPC 44:0;4) are shown as peak areas (arbitrary unit [a.u.]). **(d–g)** Measurements of the of the complex SPs IPC (IPC 44:0;3 [d] and IPC 44:0;4 [e]) and MIPC (MIPC 44:0;3 [f] and MIPC 44:0;4 [g]) in WT (black), *svf1 Δ* (dark gray), *sec12^{ts}* (light gray), and *svf1 Δ sec12^{ts}* (white) cells at the restrictive temperature (37°C). Error bars represent standard deviation from mean. **(h–k)** Measurements of the of the complex SPs IPC (IPC 44:0;3 [h] and IPC 44:0;4 [i]) and MIPC (MIPC 44:0;3 [j] and MIPC 44:0;4 [k]) in WT, *svf1 Δ* , *nvj2 Δ* , *svf1 Δ nvj2 Δ* , *osh2 Δ osh3 Δ osh4 Δ* , *osh2 Δ osh3 Δ osh4 Δ svf1 Δ* , *osh2 Δ osh3 Δ osh4 Δ nvj2 Δ* , and *osh2 Δ osh3 Δ osh4 Δ svf1 Δ nvj2 Δ* cells. The color code is indicated below. Error bars represent standard deviation from mean. **(l)** Flux analysis shows the incorporation of ²H₆-inositol and ¹³C₃¹⁵N-serine into IPC species (44:0;3 and 44:0;4). Unlabeled IPC, inositol only labeled IPC (+²H₆), serine only labeled IPC (+¹³C₃¹⁵N) and double labeled IPC (+¹³C₂²H₆¹⁵N) are shown in *svf1 Δ* , *svf1 Δ pl.Svf1-GFP* and *svf1 Δ pl.Svf1_{V12D}-GFP* at the time point $t = -15$ min and $t = 90$ min related to the addition of the tracers at $t = 0$ min. The IPC levels are expressed in pmol/0.4 OD units. **(m)** Flux analysis shows the incorporation of ¹³C₃¹⁵N-serine into PS species (34:2 and 34:1). Unlabeled PS and serine labeled PS (+¹³C₃¹⁵N) are shown in *svf1 Δ* , *svf1 Δ pl.Svf1-GFP* and *svf1 Δ pl.Svf1_{V12D}-GFP* at the time point $t = -15$ min and $t = 90$ min related to the addition of the tracer at $t = 0$ min. The PS level is expressed in pmol/0.4 OD units. **(n)** Flux analysis shows the incorporation of ²H₆-inositol into PI 34:1 species. Unlabeled PI and inositol labeled PI (+²H₆) are shown in *svf1 Δ* , *svf1 Δ pl.Svf1-GFP* and *svf1 Δ pl.Svf1_{V12D}-GFP* at the time point $t = -15$ min and $t = 90$ min related to the addition of the tracers at $t = 0$ min. The PI levels are expressed in pmol/0.4 OD units. **(o)** Serial dilutions of WT, *svf1 Δ* , *nvj2 Δ* , *svf1 Δ nvj2 Δ* , *dga1 Δ lro1 Δ are1 Δ are2 Δ* ($\Delta 4$), $\Delta 4svf1 $\Delta$$, $\Delta 4nvj2 $\Delta$$, and $\Delta 4svf1 Δ nvj2 $\Delta$$ on YPD plates (control) and YPD plates containing 20nM Aurobasidin A (Aba). Bars represent mean \pm SD from three independent samples.

stable and had the expected molecular weight based on SDS-PAGE and mass photometry experiments (Fig. S7). We used the purified proteins to extract lipids and determined the amount of co-purified ceramide 44:0;4 and, as a control, 34:1 phosphatidylcholine (PC 34:1) using targeted lipidomics (Fig. 7, d and e). We detected 44:0;4 ceramide co-purified with Svf1 in high amounts compared to general ceramide levels in the cell. Both Svf1 mutants yielded similar amounts of ceramide bound to the proteins, suggesting that Svf1 binds ceramide independent of its AH (Fig. 7 d). In contrast, the amounts of PC co-purified with the protein were strongly depending on the amphipathic character of the helix, suggesting that phospholipids are bound to the AH itself, consistent with its function in organelle targeting (Fig. 7 e). This suggests that Svf1 is able to extract ceramide from membranes independent of its AH.

Based on these data, we aimed at identifying mutations in Svf1 that interfere with ceramide binding. Most of the amino acids in the cleft between the two lipocalin domains are hydrophobic and changing them can interfere with folding of the entire protein. We were unable to identify mutations that add large hydrophobic headgroups that generate additional mass, blocking ceramide from entrance into the pocket. We therefore focused on two histidine residues located in a small α -helical stretch that lies over the potential ceramide binding pocket (Fig. 7 f). Mutation of both histidines to alanines (H273A/H274A) resulted in the purification of a stable protein (Fig. S7, d and e). However, we could barely detect any co-purified ceramide 44:0;4 showing that ceramide binding was almost completely blocked in this mutant (Fig. 7 d). Interestingly, we were also not able to detect any significant amount of co-purified PC 34:1, suggesting that the AH of Svf1 was also affected by the mutations (Fig. 7 e). In line with these results, expressing the GFP tagged Svf1^{H273A/H274A} mutant in cells led to a complete loss of co-localization with the Mnn9 positive cis-Golgi structures compared to WT Svf1-GFP (Fig. 7 g). The Svf1^{H273A/H274A} mutant did not rescue the negative genetic interaction between SVF1 and SUR2 (Fig. 7 h). Together, our results show that the two histidines in the cap region are required for ceramide binding and targeting of Svf1 to the Golgi apparatus. Based on the molecular docking studies, one of the histidines can potentially interact with the apolar C26 acyl chain of the ceramide. However, the other histidine is, based on the structure predictions, close to a negatively charged aspartate in

the AH. It is possible that the presence of ceramide in the binding pocket of Svf1 could lead to a protein rearrangement that brings the AH in a stable conformation that is than targeting the Golgi apparatus. However, this can only be determined by solving the structure of the protein. Taken together, our data suggest that Svf1 is a ceramide-binding protein that affects the conversion of ceramides to cSPs at the cis-Golgi, most likely by the transfer of ceramides from the ER to the Golgi apparatus.

Discussion

Here we showed that the yeast protein Svf1 is a ceramide-binding protein. Svf1 harbors two lipocalin domains (Flower, 1996) with a hydrophobic cleft in between that allows the accommodation of ceramides. The deletion of SVF1 results in the accumulation of ceramides with a concomitant decrease in complex SPs suggesting that Svf1 transports ceramides between the ER, where they are synthesized, and the Golgi apparatus where they are used as a substrate for the biosynthesis of complex SPs (Körner and Fröhlich, 2022). Accordingly, we detected a Svf1 pool that is dynamically localized at the cis-Golgi apparatus as well as a cytosolic pool. In addition, immunopurification of Svf1 yields potential interaction partners from both organelles, the ER and the Golgi apparatus. For its Golgi targeting, Svf1 requires its N-terminal-AH helix as well as an N-terminal acetylation, similar to other proteins that target the Golgi via an AH (Behnia et al., 2007). In addition, we identified two histidine residues in a small predicted α -helical cap that are important for keeping ceramide in the binding pocket as well as cis-Golgi targeting of the protein.

In summary, we proposed a model where Svf1-mediated non-vesicular ceramide transport acts in parallel to the vesicular transport pathway (Fig. 8). In this model, Svf1 first picks up ceramide from the ER. The interaction of Svf1 appears to be very transient as we can only detect Svf1 at the ER when the two glycines in its AH are exchanged for alanines. The accommodation of ceramide in the binding pocket of Svf1 is directly dependent on the two histidines in the cap region of a small α -helix. Svf1 is then targeted to the Golgi apparatus via its AH. This specificity of this targeting might rely on a marker lipid at the Golgi, such as PI4P or a yet unidentified protein interaction partner of Svf1. Ceramides are released at the Golgi and used as a




Figure 7. Svf1 binds ceramide in a hydrophobic pocket between its two lipocalin domains. (a) AlphaFold prediction of the structure of Svf1. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100 according to the color code. (b) Different visualization of the predicted structure of Svf1 with its two lipocalin domains colored in blue and in purple and the N-terminal AH color coded in orange. (c) Results of the molecular docking studies. A 44:0;4 ceramide (purple) can be accommodated in the hydrophobic cleft between the two lipocalin domains. Amino acids and the ceramide headgroup are shown as balls and sticks in the enlarged view. (d and e) Targeted lipidomic analysis of ceramide 44:0;4 and (e) PC 16:0/18:1 extracted from the purified proteins. Proteins were purified via a FLAG-tag and extracts were used for chloroform methanol extraction of co-purified lipids. Lipids co-purified with Svf1-FLAG (black), Svf1_{V12D}-FLAG (dark gray), Svf1_{G7A/G8A}-FLAG (medium gray) and Svf1_{H273A/H274A}-FLAG (light gray) are shown. Bars represent mean ± SD from four independent samples. (f) Cartoon model of the predicted structure of Svf1 with the AH helix colored in light orange and the small α -helical cap colored in dark orange. The two side chains of the histidines H273 and H274 are shown. (g) Co-localization of GFP tagged Svf1 expressed from a plasmid under control of the endogenous promoter with mKate tagged Mnn9 and Halo tagged Sec63 for the WT (upper panel) and the H273A H274A mutant (lower panel). Scale bar = 5 μ M. (h) Tetrad analysis of the *svf1* Δ :*pl.Svf1*_{H273A/H274A}-GFP (blue and green, respectively) mutants crossed with *sur2* Δ (red). Source data are available for this figure: SourceData F7.




Figure 8. Model for the proposed function of Svf1 in ceramide transport at the ER-Golgi interface. A model for vesicular and non-vesicular ceramide transport in yeast under normal growth conditions. Ceramides are transported by vesicular transport while Nvj2 resides in the NVJ. Under these conditions Svf1 transports ceramides in a non-vesicular pathway. Svf1 first picks up ceramide in the ER in a transient interaction with the organelle. Svf1 targets the cis-Golgi apparatus and releases ceramides that is then metabolized into cSPs.

substrate for the biosynthesis of cSPs (Fig. 8). The AH must have some very specific properties, as the replacement of the AH of Svf1 with that of Grh1 does not allow targeting of the Golgi. The targeting of Svf1 to the cis-Golgi might also directly depend on the close proximity of ER exit sites and the cis Golgi apparatus (Ikeda et al., 2020; Kurokawa et al., 2014). In an alternative model, Svf1 is not directly transporting ceramides but rather acts as a sensor for ceramides that then regulates Aur1 activity in the Golgi apparatus. Since Svf1 mainly localizes at the cis Golgi marked by Mnn9 and not the medial Golgi marked by Aur1, we favored the first model where Svf1 acts as a ceramide transport protein.

Another important question is how ceramide is released from the hydrophobic pocket of Svf1. At the moment, we can only speculate about this without having structural data on Svf1 available. It is important to highlight that our results depend on structure predictions based on the AlphaFold algorithm (Varadi et al., 2022; Jumper et al., 2021). However, one possible model is that ceramide is exchanged via another lipid at the Golgi apparatus. An attractive candidate would be diacylglycerol (DAG) as a product of complex SP biosynthesis. It remains after the phosphoinositol headgroup of PI is transferred to ceramide. DAG, similar to ceramide only harbors a hydroxyl group as a headgroup, allowing both of the molecules to flip between the two leaflets of the Golgi membrane (Holthuis and Levine, 2005). Determining the mechanism of ceramide release at the Golgi will be an important point to address in the future.

As mentioned before, several different pathways contribute to ceramide transport in yeast. Non-vesicular transport depends on the Nvj2 protein. This pathway is mainly active under conditions of artificial ER stress and transports ceramides preferably to the medial-Golgi (Liu et al., 2017). In addition, yeast tricalbins have also been implicated in non-vesicular ceramide transport (Ikeda et al., 2020). In mammalian cells, the majority of ceramides are transported by CERT (Hanada et al., 2003). Some ceramides that are substrates for the biogenesis of

glycosyl-ceramides appear to be also transported by vesicular transport (Halter et al., 2007). Vesicular transport in yeast depends on the COP-II machinery and accounts for about 60–80% of ceramides transported (Funato and Riezman, 2001). In yeast, the Osh proteins have also been implicated in vesicular ceramide transport, but the molecular mechanism remains unknown (Kajiura et al., 2014). Osh4 is clearly described as lipid transfer protein that exchanges sterols for PI4Ps between the ER and the Golgi apparatus (de Saint-Jean et al., 2011). Osh2 is the homolog of Osh1, which localizes at the nuclear vacuolar junction (NVJ; Olkkonen, 2015; Kvam and Goldfarb, 2004), but its exact role here has not been determined. Osh3 is mainly found at ER plasma membrane contact sites where also the tricalbins play an important role (Olkkonen, 2015; Stefan et al., 2011). In summary, the effects of the triple knockout of *OSH2*, *OSH3*, and *OSH4* on ceramide transport are more likely the result of an overall metabolic adaptation of yeast cells to changes in lipid transport and or metabolism. Based on our lipidomics experiments, Svf1 acts in a parallel pathway to COP-II-dependent vesicular transport and Nvj2 mediated non-vesicular transport (Fig. 8). Especially the latter could be viewed as a detoxification mechanism that becomes active once ceramides accumulate in the ER and cause ER stress. Alternatively, Nvj2 could also transport ceramides at the NVJ. Another protein localizing to the NVJ, yeast Cvm1, has recently been suggested to function in SP and ceramide homeostasis (Bisinski et al., 2022). However, yeast cells have multiple mechanisms to transport ceramides between the ER and the Golgi and potentially between other organelles. One explanation could be that ceramides are toxic to cells when they accumulate (Eisenberg and Büttner, 2014). This is also supported by the detoxification mechanism resulting in the acylation of ceramides allowing the cell to store them in lipid droplets (Voynova et al., 2012).

Finally, is the function of Svf1 conserved? Svf1 belongs to the family of lipocalins (Flower, 1996; Lu et al., 2020). While the lipocalin fold is a highly conserved structure, its sequence conservation is very low (Flower, 1996). This makes it difficult to identify homologs of Svf1 in higher eukaryotes. Based on our data, proteins harboring two lipocalin domains are likely candidates for ceramide transporting Svf1 homologs. However, lipocalins have been implicated in the transport and solubilization of small hydrophobic molecules, e.g., fatty acids and other lipids. Prominent examples are the fatty acid binding proteins (Smathers and Petersen, 2011) that are described as transport proteins for a variety of fatty acids (McArthur et al., 1999). Since we also detect interactions between Svf1 and the VLCFA elongation complex, a handover of activated VLCFAs to the ceramide synthases would be an attractive model for the molecular function of Svf1. While the lack of Svf1 would then also result in lower levels of complex SPs, this model is contrary to the increase of ceramides we are observing in *svf1Δ* cells. A direct interaction of ceramides and a lipocalin protein have also been observed for the tear lipocalin protein (Glasgow and Abduragimov, 2018). It thus remains possible that a lipocalin protein has a similar function to Svf1 in higher eukaryotes. Along this line, it is especially interesting that ceramides transported by CERT are usually containing C16 or C18 acyl

chains (Loizides-Mangold et al., 2012). Sorting of VLCFA-containing ceramides by lipocalin domain containing proteins could thus be an evolutionary conserved mechanism.

Material and methods

Yeast strains and plasmids

Yeast strains used in this study are listed in Table S2. All plasmids used in this study are described in Table S3.

Growth conditions and media

Tetrad dissections were performed on standard YPD plates and incubated at 30°C for 72 h. Yeast strains were grown according to normal growth conditions. For spotting assays, myriocin or Aureobasidin A were added at concentrations as indicated and the plates were grown at 30°C for 48 h. For SILAC experiments SDC medium without lysine with 2% glucose, 6.7 g/liter yeast nitrogen base without amino acids and yeast synthetic dropout without lysine (Sigma-Aldrich) was used. Normal or heavy lysine (L-lysine $^{13}\text{C}_6^{15}\text{N}_2$; Cambridge Isotope Laboratories) at the concentration of 30 g/liter were added. Cells were diluted from an overnight pre-culture to an $\text{OD}_{600} = 0.2$ and grown at 30°C. Cells were harvested at an $\text{OD}_{600} = 1.0$ – 1.4 .

Colony size quantification

For the quantification of colony size, ImageJ was used. The obtained image was converted to a binary. A circle was placed around each tetrad, and the mean intensity values were measured.

FastCloning

For an insertion of a DNA fragment into a vector, the FastCloning method established by Li et al. (2011) was used. In short, fragments were amplified with 15–17 bp homologous overlapping overhangs at both ends to the opposite fragment. After digestion of the initial methylated DNA by DpnI at 37°C for 1 h, the fragments were transformed in a 1:1 M ratio followed by homologous recombination in *E. coli* DH5 α competent cells.

Q5 mutagenesis

The Q5 mutagenesis method was used to generate deletions or point mutations in a desired DNA locus. Primers were designed using NEBaseChanger (New England BioLabs, Inc.; version 1.3.2; Table 1). After amplification of the desired DNA fragment, the initial DNA was digested by DpnI at 37°C for 1 h. After a PCR clean up (NucleoSpin Gel and PCR Clean-up; Macherey-Nagel) the PCR fragment was phosphorylated by the T4 PNK Polynucleotide Kinase (New England BioLabs Inc.) for 30 min at 37°C and afterwards ligated by the T4 DNA ligase over night at 4°C.

Fluorescence microscopy

Cells were grown to logarithmic growth phase in synthetic medium supplemented with essential amino acids (SDC). For the visualization of the Halo tag, one OD unit cells were centrifuged and resuspended in 50 μl SDC medium. Then, 0.625 μl Janelia Fluor646 HaloTag Ligand (stock concentration: 200 μM ; Promega) were added and the cells were incubated for 30 min at 30°C

shaking. Afterwards, the cells were washed 10 times with 1 ml SDC medium, transferred to a new tube and were used for imaging. Cells were imaged live in SDC medium on an Olympus IX-71 inverted microscope equipped with 100 \times NA 1.49 and 60 \times NA 1.40 objectives, a sCMOS camera (PCO), an InsightSSI illumination system 4',6-diamidino-2-phenylindole, GFP, mCherry, and CY5 filters, and SoftWoRx software (Applied Precision). We used constrained-iterative deconvolution (SoftWoRx). ImageJ (National Institutes of Health; RRID:SCR_003070) was used for the processing and quantification of the images.

Statistical analysis

Statistical analysis was based on two-sided *t* tests when two conditions were compared: *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. For microscopy experiments, the statistical comparisons were performed among the means of individual experiments, not based on data points for individual cells. For SILAC plots (ratio versus intensity), the *P* value was defined as significance *A* as described before (Cox and Mann, 2008). Significant outliers are colored in red ($P < 1e^{-14}$), orange ($P < 0.0001$), or steelblue ($P < 0.05$); other proteins are shown in light blue.

Western blot

Samples prepared from cell lysates or in the membrane fractionation assay were used for Western blot analysis. GFP-tagged proteins were detected with a mouse anti-GFP (RRID: AB_390913; Roche) antibody diluted 1:1,000. Pgk1 was detected with a 1:10,000 diluted mouse anti-Pgk1 (RRID:AB_2532235; Thermo Fisher Scientific) antibody using a horseradish peroxidase-coupled mouse IgG kappa binding protein (RRID: AB_2686626; Santa Cruz Biotechnology). Sec61 was detected with a 1:10,000 diluted rabbit anti-Sec61 (Ungermann lab; University of Osnabrück, Osnabrück, Germany; Gao et al., 2018) and Gas1 with a polyclonal rabbit anti-Gas1 (Miller lab; University of Cambridge, Cambridge, UK). The luminal domain of Gas1 was expressed as a His-tagged fusion in *E. coli* and purified by Ni-affinity chromatography. Purified protein was injected into rabbits, pre-screened for low cross-reactivity to yeast lysate. Polyclonal sera were collected and tested by immunoblotting and radioactive immunoprecipitation from yeast lysates, both yielding specific recognition of the appropriate protein. Antibodies from the Schekman lab prepared similarly were used as a benchmark (Doering and Schekman, 1997). Antibody using a horseradish peroxidase coupled mouse anti-rabbit IgG binding protein (RRID:AB_628497; Santa Cruz Biotechnology). Western blots were acquired on a BioRad (www.biorad.com) Chemidoc XRS + imager and quantified using the ImageJ software package ImageJ (RRID:SCR_003070; National Institutes of Health, Bethesda, MD) or via exposure on film.

Proteomics

Proteomics analysis was performed as described previously (Fröhlich et al., 2013). Briefly, cells were grown in SDC medium containing either light or heavy lysine to a concentration of 30 mg/ml. Main cultures were inoculated in 500 ml SDC medium to an OD_{600} 0.1 from a pre-culture containing light or heavy lysine (30 mg/ml) and grown over day to an OD_{600}

Table 1. **Primer list**

Name	Sequence
Svf1_S1	5'-TGCATCGAATCAAGAAAAAGAAACGAATAAGCTTTTGTATAATATAATATAATGCGTACGCTGCAGGTGCAC-3'
Svf1_S2	5'-GTAGTATTAATCACAGATAGGAAAAAGCATACGAGACCTTCCCACCTTTTGTCTCAATCGATGAATTCGAGCTCG-3'
Svf1_S3	5'-CATTCAATTTCTGAATCAGATGTGATTAGTGAGGAGTCTTACAATGAAGCACGTACGCTGCAGGTGCAC-3'
Svf1_pom_n_GFP_fo	5'-AATCAAGAAAAAGAAACGAATAAGCTTTTGTATAATATAATATAATGTGCGAGGTGCACAACCCCTAAT-3'
Svf1_pom_n_GFP_re	5'-AGCCATACCAGTGACTGTGAGATCCACCTTTTATCCACTTCAAGCGGCCGCATAGGCCACT-3'
SUR2_S1	5'-TAACATTCTAGTCCGAAGAGGGTGTATACGAAAAGAAAATACGATGCGTACGCTGCAGGTGCAC-3'
SUR2_S2	5'-GACATTGCCTTTACCCAGCAATTGAACGGGAGGTATGCAAAAAGGGTTAATCGATGAATTCGAGCTCG-3'
Nvj2_S1	5'-CATCGAAGAGCAGAACAGCAAGAGAAAAGTAGCATTAAAAGACCATAATGCGTACGCTGCAGGTGCAC-3'
Nvj2_S2	5'-GCTTCAAGTGATATTTATTTATTTTAAATATAGTACCGTGGACTCAATCGATGAATTCGAGCTCG-3'
Mak3_S1	5'-GATTACAAGATAAAAAAGCCACTACTACAGAAAAGGCGTTGGTTCAGGACATGCGTACGCTGCAGGTGCAC-3'
Mak3_S2	5'-GTATTATTAATATATATTTTATCATCATCGAGTGTTCCTTTAATCGATGAATTCGAGCTCG-3'
Svf1_V12D_for	5'-ATCTCAGCAGACACTGGTATG-3'
Svf1_V12D_rev	5'-CCCACCTTTTATCCACTTC-3'
Ydr222w_S1	5'-GTGAGGGCGTATAAGATACATCGTACATACATAGAGACTCATTTAGTGATGCGTACGCTGCAGGTGCAC-3'
Ydr222w_S2	5'-GAAAAAAGGACAAAAACGAATTCATGTGGAAGGTTCCAGCTTTTGTCAATCGATGAATTCGAGCTCG-3'
Ylr225c_S1	5'-GGGCAACGAACAGTTAATTAACATAAAAAATCATAGAGCAAGAAAAAATGCGTACGCTGCAGGTGCAC-3'
Ylr225c_S2	5'-GATATAATATCTTGAATGATGAAAATATGTATAGTCAAATTCATTTTTTCAATCGATGAATTCGAGCTCG-3'
Svf1_G7AG8A_Q5_for	5'-TGGATAAAAGCTGCGATCTCAGCAGTC-3'
Svf1_G7AG8A_Q5_rev	5'-CTTCAACATTATATTATATTATACAAAAGC-3'
Osh2_S1	5'-ATATTTTCATCGATAATCATAAGCTTAAGCTCGCCAACGAAAACCTCACAATATGCGTACGCTGCAGGTGCAC-3'
Osh2_S2	5'-CATTCAAATACATACAAGTACCAGGAAAAAGCTCGCATAAAAAAGGCGTGTTAATCGATGAATTCGAGCTCG-3'
Osh3_S1	5'-ATTTGCTGGAGAGTAGTAAAACGAGCTTGAATAGCAGCTGCGAATCGAATTATGCGTACGCTGCAGGTGCAC-3'
Osh3_S2	5'-ATAAATAGAGTACAAAGGGGGAAAAAGTTCACCTGATGTCATCAAGGCATTCAATCGATGAATTCGAGCTCG-3'
Osh4_S1	5'-CCTAGAAACAAATCGAAAAATTTATAAGATTTAGTCTCAAGAATTTCAAGTCATGCGTACGCTGCAGGTGCAC-3'
Osh4_S2	5'-GATAGATAATATATTAGTGCAACGGTAACAAGTTGTTACTTTATCGTTCTCCTTAATCGATGAATTCGAGCTCG-3'
Sec31_S2	5'-CAAGGCCAATACGCCACTTTTTGACTGAAAGTTTTGAGACTGAATTAATCGATGAATTCGAGCTCG-3'
Sec31_S3	5'-CTGGCTGACAGGAGTGAAGAGGTTGATTGGCATAGCTGAAGCGACTTTGAATCGTACGCTGCAGGTGCAC-3'
Nvj2_pRS_KO_for	5'-GGTTTTGAACACATCGAAGAGCAGAACAGCAAGAGAAAAGTAGCATTAAAAGACCAGATTGACTGAGAGTGCAC-3'
Nvj2_pRS_KO_rev	5'-GCATATAGCTTCAAGTGATATTTATTTATTTTAAATATAGTACCGTGGACCTGTGCGGTATTTACACCCG-3'
Q5_L2E_for	5'-TAATATAATGGAGAAGTGGATAAAAGGTG-3'
Q5_L2E_rev	5'-TATTATACAAAAGCTTATTCGTTTC-3'
HAHA_for	5'-CATGAAGCCTGCTGCCGAGCTAAGG-3'
HAHA_rev	5'-CCTTGAAGGCCATTATAAATG-3'
AUR1_S2	5'-ATATGTATCTACATAAGACCAACCGTATCCGTAATTGCAGATAAAAATACTCATTAAATCGATGAATTCGAGCTCG-3'
AUR1_S3	5'-TTCTGTTTCTCGTTCGTCGCCACGCTATAACGTCAGTGTAAAGAGGGCTCGTACGCTGCAGGTGCAC-3'
Svf1_19aa_for_Grh1_AH	5'-GGACTTTTGAGCAGAGCGTGAAGATGAATATGGGAAAGATTACATTCATAGTG-3'
Svf1_pr_rev_oh_Grh1AH	5'-GTACGAGGTTTTAGCTATTCTAAACATTATATTATATTATACAAAAGCTTATTGTTTTTC-3'
GFP_for_oh_Svf1	5'-AGTCTTACAATGAAGCACGTACGCTGCAGGTGCAGCG-3'
GFP_rev_oh_Svf1_t	5'-GACCTTCCCCTTTTGTCTATTGTACAATTCATCCATACC-3'
pRS405Svf1_term_f	5'-ATGAATTGTACAAATAAGCAAAGTGGGAAGGTCTCG-3'
pRS405Svf1_rev_oh	5'-TCGACCTGCAGCGTACGCTGCTTCATTGTAAGACTCCTCAC-3'
pRS405Svf1_AH_GFP_Q5mut_for	5'-CGTACGCTGCAGGTGCAC-3'
pRS405Svf1_AH_GFP_Q5mut_rev	5'-AGGCTCAGCCATACCAGTG-3'
Galpr_for_oh_pRS	5'-CCGGGCCCCCCCTCGAGTGAAGTACGGATTAGAAGCC-3'

Table 1. **Primer list (Continued)**

Name	Sequence
Galpr_rev_oh_Svf1	5'-TTTATCCACTTCAACATGTTTTTCTCCTTGACGTTAAAG-3'
Svf1_for_oh_Galpr	5'-CGTCAAGGAGAAAAACATGTTGAAGTGGATAAAAGGTG-3'
pRS_rev_oh_Galpr	5'-TTCTAATCCGTACTTCACTCGAGGGGGGCCGG-3'
Svf1_term_oh_3xFlag	5'-TACAAAGATGACGACGATAAGGATTATAAGGACGACGACGACAAATAATCGTATGCTTTT-3'
Svf1_rev_3xFLAG_oh	5'-TCGTCGTCATCTTTGTAGTCCTTGCATCATCATCCTTGAATCTGCTTCATTGTAAGAC-3'
Mnn9_S2	5'-TCTTTCAATAACGCTATAGCTTCTGTATGCTTTTTGCTCAGTTGCTCAATCGATGAATTCGAGCTCG-3'
Mnn9_S3	5'-TTTGGCTTACCAACTATTTGGTTTATCATATAGAGGAAGAGAACCATCGTACCGCTGCAGGTCGAC-3'
Sec63_S2	5'-ATACGCTAAGAGCTAAAATGAAAACTATACTAATCACTTATATCTAATCGATGAATTCGAGCTCG-3'
Sec63_S3	5'-ACTGATATCGATACGGATACAGAAGCTGAAGATGATGAATCACCAGAACGTACCCTGCAGGTCGAC-3'
Sec7_S2	5'-TTCTACAACCTAAGCATATTTAATCTGCTGGACCATTCAACAAAGCCTTAATCGATGAATTCGAGCTCG-3'
Sec7_S3	5'-CTATAAAACAATTTCTAAGCAGAGTTGGTGAATTATACCTTTCTACTGATCGTACCCTGCAGGTCGAC-3'
Vps4_S2	5'-TATTTTCATGTACACAAGAAATCTACATTAGCACGTTAATCAATTGACTAATCGATGAATTCGAGCTCG-3'
Vps4_S3	5'-GACTTGCTGAAGCAAGAACAGTTCACTAGAGATTTGGTCAAGAAGGTAACCGTACCCTGCAGGTCGAC-3'
Lys2_S1	5'-GAAAACTGCTAATTATAGAGAGATATCAGAGTTACTCACTAATGCGTACCCTGCAGGTCGAC-3'
Lys2_S2	5'-CATATTTAATTATTGTACATGGACATATCATACGTAATGCTCAACCTTAATCGATGAATTCGAGCTCG-3'

0.7–1.2. The same amount of OD units from both cultures were harvested at 4,000 rpm, 4°C for 5 min, washed with ice cold water, and snap-frozen as pellets. Cells were lysed with 500 µl acid-washed glass beads in 500 µl GFP-Trap pull-down buffer (20 mM HEPES, pH 7.4, 150 mM potassium acetate, 5% glycerol, 1% n-octyl-β-D-glucoside and 1 pill/10 ml buffer cOmplete Protease Inhibitor Cocktail EDTA free (Roche) using the FastPrep (MP biomedical). After a centrifugation step at 14,000 rpm and 4°C for 10 min, the supernatants of light and heavy lysine-cultured strains were incubated for 10 min at RT on a turning wheel with 12.5 µl in GFP-Trap pull-down buffer equilibrated GFP Trap beads (Chromotek). The beads were washed in total six times first with the pull-down buffer and then with the washing buffer (20 mM HEPES pH 7.4, 150 mM potassium acetate, 5% glycerol). Afterwards, the beads were combined and the proteins on the beads were reduced, alkylated and digested with LysC at 37°C overnight. Resulting peptides were transferred to a glass vial and 10 µl were used to perform reversed-phase chromatography on a Thermo Ultimate 3000 RSLCnano system connected to a QExactivePLUS mass spectrometer (Thermo Fisher Scientific) through a nano-electrospray ion source. Peptides were separated on a 50-cm PepMap C18 easy spray column (Thermo Fisher Scientific) with an inner diameter of 75 µm. The column temperature was kept at 40°C. The peptides were eluted from the column via a linear gradient of acetonitrile from 12 to 35% in 0.1% formic acid for 80 min at a constant flow rate of 250 nl/min followed by a 20 min increase to 60% and finally 10 min to reach 90% buffer B. Eluted peptides from the column were directly electro sprayed into the mass spectrometer. Mass spectra were acquired on the Q ExactivePlus in a data-dependent mode to automatically switch between full scan MS and up to ten data-dependent MS/MS scans. The maximum injection time for full scans was 50 ms, with a target value of 3,000,000 at a resolution of 70,000 at *m/z* 200. The 10

most intense multiply charged ions ($z \geq 2$) from the survey scan were selected with an isolation width of 1.6 Th and fragment with higher energy collision dissociation (Olsen et al., 2007) with normalized collision energies of 27. Target values for MS/MS were set at 100,000 with a maximum injection time of 80 ms at a resolution of 17,500 at *m/z* 200. To avoid repetitive sequencing, the dynamic exclusion of sequenced peptides was set at 20 s. The resulting MS and MS/MS spectra were analyzed using MaxQuant (version 2.0.1.0, www.maxquant.org/; Cox and Mann, 2008; Cox et al., 2011). All calculations and plots were performed using the R software package (www.r-project.org/; RRID: SCR_001905). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD039395 and <http://www.ebi.ac.uk/pride/archive/projects/PXD039395>.

Lipidomics

For the LC-MS/MS analysis of LCB and ceramides, cells were grown in YPD to exponential growth phase. As an internal standard for normalization and quantification ceramide (CER d18:1/17:0; Avanti) was spiked prior to the lipid extraction. Lipids were extracted from lysed yeast cells corresponding to 200 µg of protein by chloroform/methanol extraction (Ejsing et al., 2009). External standard lipids (PE 17:0/14:1; PS 17:0/14:1; PI 17:0/14:1; PC 17:0/14:1; LCB d17:1; CER d18:1 17:0; all Avanti) were used for the calculation of a standard curve and calculation of lipid amounts. Dried lipid films were dissolved in a 65:35 (v/v) mixture of the mobile phases A (60:40 water/acetonitrile, 10 mM ammonium formate and 0.1% formic acid) and B (88:10: 2 2-propanol/acetonitrile/water, 2 mM ammonium formate and 0.02% formic acid). A C30 reverse-phase column (Thermo Acclaim, C30, 2.1 × 250 mm, 3 µm, operated at 50°C; Thermo Fisher Scientific) connected to Shimadzu Nexera HPLC system and a

ExactivePlus Orbitrap mass spectrometer equipped with a heated electrospray ionization (HESI) probe was used, as previously described (Eising et al., 2019). Peaks were analyzed using the Lipid Search algorithm (MKI). Peaks were defined through raw files, accurate m/z values of product ions and precursor ions. Candidate molecular species were identified by database (>1,000,000 entries) search of positive (+H⁺; +NH₄⁺) or negative (-H⁻; +HCOO⁻) adducts. Mass tolerance was set to ± 5 ppm for the precursor and fragment m/z values. Samples were aligned within a retention time window of 0.5 min and results combined in a single report. From the intensities of the lipid standard, the absolute values for each lipid in pmol/ μ g protein were calculated. For complex SPs, no standards are commercially available. Therefore, IPC and MIPC data are represented as area under the peak quantified with Thermo freestyle or Skyline (Pino et al., 2020; Peng et al., 2020; MacLean et al., 2010) software. A PI standard also measured in negative ion mode was used to normalize the values between the different samples.

COPII budding assay

Yeast microsomal membranes were prepared as previously described (Wuestehube and Schekman, 1992). Briefly, exponential growth phase yeast cells grown in YPD (1% w/v yeast extract, 2% w/v peptone, and 2% w/v glucose) were harvested and resuspended in 100 mM Tris, pH 9.4, 10 mM DTT to 40 OD₆₀₀/ml and incubated at RT for 10 min. Cells were pelleted and resuspended to 40 OD₆₀₀/ml in lyticase buffer (0.7 M sorbitol, 0.75 \times YPD, 10 mM Tris, pH 7.4, and 1 mM DTT + 2 μ l/OD₆₀₀ lyticase) and then incubated for 30 min at 30°C with gentle agitation. Cells were pelleted, washed once with 2 \times JR buffer (0.4 M sorbitol, 100 mM potassium acetate, 4 mM EDTA, 40 mM HEPES, pH 7.4, 2 mM DTT, and 2 mM PMSF) at 100 OD₆₀₀/ml and then resuspended in 2 \times JR buffer at 400 OD₆₀₀/ml before freezing at -80°C. Spheroplasts were thawed on ice and an equal volume of ice cold dH₂O (with 2 mM DTT and 2 mM PMSF) was added before disruption with a motor-driven Potter Elvehjem homogenizer at 4°C. The homogenate was cleared by low-speed centrifugation (750 g , 5 min, 4°C) and crude membranes collected by centrifugation of the low-speed supernatant at 27,000 g . The membrane pellet was resuspended in 1 ml/l of cells used of buffer B88 (20 mM HEPES, pH 6.8, 250 mM sorbitol, 150 mM potassium acetate and 5 mM magnesium acetate) and loaded onto a step sucrose gradient composed of 1 ml 1.5 M sucrose in B88 and 1 ml 1.2 M sucrose in B88. Gradients were subjected to ultracentrifugation at 190,000 g for 1 h at 4°C. Microsomal membranes were collected from the 1.2 M/1.5 M sucrose interface, diluted 10-fold in B88, and collected by centrifugation at 27,000 g . The microsomal pellet was resuspended in a small volume of B88, aliquoted in 1 mg total protein aliquots and snap-frozen in liquid nitrogen.

Budding reactions were adapted from Melero et al. (2018). Briefly, 0.66 mg of microsomal membranes per reaction were incubated in B88/ATP regeneration mix (final concentration of ATP regeneration mix is: 1 mM ATP, 50 μ M GDP-mannose, 40 mM creatine phosphate, and 200 μ g/ml creatine phosphokinase) for 15 min at 15°C. The samples were then mixed with 1 ml cold B88, pelleted (19,300 g , 3 min, 4°C) and washed twice

with 1 ml cold B88. Budding reactions were set up in B88 to a final volume of 250 μ l at the following concentrations: 40 μ g/ml Sar1, 10 μ g/ml Sec23–Sec24, 30 μ g/ml Sec13–Sec31, and 0.2 mM GTP and ATP regeneration mix. Low salt B88 (100 mM potassium acetate) was used for the coat-containing reactions and coat proteins were omitted in the negative reactions. Reactions were incubated for 25 min at 25°C and then on ice for 5 min. A 10- μ l aliquot was collected as the total fraction and the vesicle-containing supernatant was collected after pelleting the donor membrane (19,300 g 3 min, 4°C). Vesicle fractions were then collected by centrifugation in a Beckman TLA-55 rotor (55,000 rpm, 25 min, 4°C). The supernatant was removed, and the pelleted vesicles and the separated supernatant were snap-frozen in liquid nitrogen.

Targeted lipidomics analysis of COP-II vesicles and purified proteins from *S. cerevisiae*

Ceramide and phosphatidylcholine (PC) were measured specifically in COPII vesicles (only ceramide) and in Svf1 proteins purified from yeast. Prior to measurement lipids were extracted from different stages of the COPII budding assay or according to 20 μ g of purified protein by chloroform/methanol extraction as described previously (Ejsing et al., 2009). 150 mM ammonium formate was added ad 200 μ l and in addition the COP-II vesicle containing samples were shaken for 20 min. Ceramide (CER d17:1/24:0; Avanti) was added prior to lipid extraction as an internal standard. Dried lipid films were dissolved in a 50:50 (v/v) mixture of the mobile phases A (50:50 water/acetonitrile, 10 mM ammonium formate and 0.1% formic acid) and B (88:10: 2 2-propanol/acetonitrile/water, 2 mM ammonium formate and 0.02% formic acid). External standard curves were prepared using phytoceramide (CER t18:0/24:0; Cayman Chemical) and PC (PC 16:0/18:1; Avanti). Samples were run using an Accucore C30 LC column (150 \times 2.1 mm 2.6 μ m Solid Core; Thermo Fisher Scientific) connected to a Shimadzu Nexera HPLC system and a QTRAP 5500 LC-MS/MS (SCIEX) mass spectrometer. Different lipid species (CER d17:1/24:0 as a control (Avanti Polar lipids), CER 42:0;3, CER 42:0;4, CER 42:0;5, CER 44:0;3, CER 44:0;4, CER 44:0;5 and PC 34:1) were detected in a positive MRM mode with optimized transition settings within a 6 min HPLC run. For peak integration, the SciexOS software was used. The concentrations of all ceramide species were calculated using the external standard curve. The ceramide concentrations were expressed in pmol/ μ l and represented in a percentage ratio of ceramide in COPII vesicles to input. The lipid concentrations extracted from purified proteins were expressed in pmol/ μ g protein.

Lipidomic flux analysis

Yeast strains were grown in YPD. At an OD₆₀₀ of 0.8 ($t = 0$), cell suspensions were spiked with a tracer cocktail resulting in a final concentration of 4.59 mM [¹³C₃ ¹⁵N]-serine 0.22 mM [²H₆]-inositol, as previously described (Martínez-Montañés et al., 2020). At time points $t = -15$ min and $t = 90$ min, cell suspensions were incubated at 4°C for 10 min with 1 M perchloric acid. The cells were centrifuged and washed with 4°C 155 mM ammonium formate, frozen in liquid nitrogen and stored at -80°C. In-depth

lipidome analysis was performed as described previously (Martínez-Montañés et al., 2020). Shortly, yeast cell pellets (appr. 4 OD units) were resuspended in 1 ml 4°C 155 mM ammonium formate and lysed at 4°C with 400 µl of acid-washed glass beads using a Mini-Beadbeater (Biospec). Lysates corresponding with 0.4 OD units were spiked with internal lipid standards and subjected to two-step lipid extraction (Ejsing et al., 2009). Lipid extracts were vacuum evaporated and re-dissolved in 100 µl chloroform/methanol (1:2; v/v) and analyzed by MS^{ALL} (Martínez-Montañés et al., 2020) using an Orbitrap Fusion Tribid (Thermo Fisher Scientific) equipped with a TriVersa NanoMate robotic nanoflow ion source (Advion Biosciences). Lipid identification and quantification was performed using ALEX¹²³ software (Pauling et al., 2017; Ellis et al., 2018; Husen et al., 2013). The results were expressed in mol % per all detected lipids.

Membrane fractionation

For the membrane fractionation, 100 OD₆₀₀ units from yeast strains in exponential growth phase were harvested at 4°C, 4,000 rpm for 5 min. The pellets were washed with ice cold water, snap frozen and stored at -80°C. Cell lysis was performed in 250 µl acid-washed glass beads and 500 µl lysis buffer (50 mM HEPES pH 6.8, 150 mM potassium acetate, 2 mM magnesium acetate, 1 mM calcium chloride, 200 mM sorbitol, and 1 pill/10 ml buffer cOmplete Protease Inhibitor Cocktail EDTA free (Roche) using the FastPrep (MP biomedical). Two consecutive centrifugation steps at 1,000 g for 20 min were performed and after each step the supernatant was transferred into a new tube. After the second centrifugation the protein concentration was determined using Bradford reagent 1:5 diluted. Cell lysate according to 500 µg protein was taken as input and the same amount of lysate was then spun down at 45,935 g, 4°C for 30 min. The supernatant and pellet were separated, and the pellet was resuspended in the same volume as the supernatant in lysis buffer. Loading dye was added and the samples were boiled for 10 min at 95°C.

Molecular docking studies

For the molecular docking study, Svf1 structure was obtained from the Uniprot database (<https://www.uniprot.org>) [uniprot] where the three-dimensional structure prediction was obtained through the neural network-based model AlphaFold [afold]. The predicted structure has very high confidence score (per-residue confidence score pLDDT > 90) along most of the core structure, with only a few lower confidence score regions (pLDDT > 70) at the N and C terminal α -helices, and at the interbarrel loops (residues 202–245 and 362–393). These regions may have an unstructured preferred conformation in water, as confirmed by molecular dynamics simulations of an atomistic CHARMM36 model of the protein solvated in TIP4P water. Ceramide 18:0/3/26:0;1 (44:0;4) and DAG 16:0/18:1 (34:1) structures were generated and optimized by Pymol [pymol] and Avogadro (<https://avogadro.cc>) packages respectively. The UCSF Chimera program (<http://www.cgl.ucsf.edu/chimera>) and AutoDockTools 4 (<http://mgltools.scripps.edu>) were used to prepare the protein and ligand structures for input to the docking procedure by

adding Gasteiger charges. The structures were then saved in PDBQT file format, for input into AutoDock Vina version 1.1.2 (<http://vina.scripps.edu>; Trott and Olson, 2009; Eberhardt et al., 2021) Both ceramide and DAG torsions were made active (flexible) for the docking search, prioritizing the terminal parts of each chain in order not to surpass the 32 active bonds allowed by Vina. The search space was defined as a cube 75 Å on each side, centered on the protein geometric center (X, Y, Z coordinates: -4.11, 4.84, -6.17). This search space encompasses the whole protein space, as required for first blind docking. Once the blind docking was validated, the search was restricted in order to probe each barrel cavity. Cubes of 27 Å of side were placed around each barrel center (X, Y, Z coordinates: 1.5, 17.0, 10.0; and -17.0, -3, -9 respectively).

Protein purification of 3xFLAG tagged Svf1 protein from *S. cerevisiae*

Yeast cells were collected after grown for 24 h in yeast peptone (YP) medium containing 2% galactose (v/v), washed in lysis buffer (150 mM NaCl, 50 mM HEPES-NaOH [pH 7.4], 1.5 mM MgCl₂, 5% [v/v] glycerol), and resuspended in a 1:1 ratio (w/v) in lysis buffer supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 1× FY protease inhibitor mix (Serva). Resuspended cells were frozen in a drop-by-drop fashion in liquid nitrogen, pulverized in 15 × 2 min cycles at 12 CPS in a 6875D Freezer/Mill Dual-Chamber Cryogenic Grinder (SPEX SamplePrep) and thawed in lysis buffer with 1 mM PMSF, 1× FY, and 1 mM dithiothreitol (DTT). After two centrifugation steps at 5,000 and 15,000 g at 4°C for 10 and 20 min, respectively, the supernatant was added to 1.5 ml α -Flag resin (Sigma-Aldrich) and nutated for 45 min at 4°C. Beads were washed twice with 20 ml lysis buffer and bound proteins were eluted on a turning wheel for 45 min at 4°C with 3xFLAG peptide. The eluate was collected by centrifugation at 1,800 rpm, 4°C for 30 s.

Mass photometry analysis

Molecular mass photometry measurements were performed using a Refeyn Two^{MP} mass photometer (Refeyn Ltd.) and carried out in silicone gaskets placed on clean coverslips. Immediately prior to mass photometry measurements, protein samples were diluted directly in lysis buffer to 100 nM working concentration. For each acquisition, 2 µl of diluted protein were added to 18 µl lysis buffer on the gasket resulting in a final concentration of 10 nM. After autofocus stabilization, images were acquired for 60 s. Data acquisition was performed using AcquireMP and then analyzed using DiscoverMP (both Refeyn Ltd).

Online supplemental material

Fig. S1, a–d are related to Fig. 1. Fig S1, e–g are related to Fig. 3. Fig. S2 shows tetrad dissections to test functionality of N- and C-terminal tagging of Svf1. Fig. S3 shows expression checks of all Svf1 constructs used in this study. Fig. S4 is related to Fig. 4. Fig. S5 shows the results of in vitro COPII budding assays and lipidomic analysis. Fig. S6 a is related to Fig. 6, l–n. Fig S6, b and c show co-localization of Svf1 with the mid-Golgi marker Aur1. Fig. S7 is related to Fig. 7. Table S1 shows the results from the

GFP pulldown MS experiment in Fig 5 a. Table S2 shows *S. cerevisiae* strains used in this study. Table S3 shows plasmids used in this study. Table S3 shows antibodies used in this study. Video 1 shows representative midsection time lapse fluorescence microscopy of yeast cells expressing Svfl1-GFP and Mnn9-mCherry.

Acknowledgments

We thank members of the Fröhlich and Ungermann labs for critical comments on the manuscript, and Alejandro Melero Carrillo for advice on COPII budding for lipidomics.

This research was supported by the VILLUM Foundation (VKR023439 to C.S. Ejsing), the VILLUM Center for Bioanalytical Sciences (VKR023179 to C.S. Ejsing), the Lundbeckfonden (R54-A5858, C.S. Ejsing) and the UK Medical Research Council (MRC_UP_12-1/10 to E.A. Miller). Sergej Limar is a member of the UOS funded graduate school “EvoCell.” Florian Fröhlich is supported by the DFG grants FR 3647/3-1, FR 3647/4-1, and SFB944.

Author contributions: Investigation: S. Limar, C. Körner, F. Martínez-Montañés, V.G. Stancheva, V.N. Wolf, S. Walter, E.A. Miller, C.S. Ejsing, V.V. Galassi, F. Fröhlich. Formal analysis: S. Limar, C. Körner, F. Martínez-Montañés, V.G. Stancheva, V.N. Wolf. Visualization: S. Limar, C. Körner, F. Martínez-Montañés, V.G. Stancheva, V.N. Wolf, F. Fröhlich. Conceptualization: S. Limar, F. Fröhlich. Funding acquisition: E.A. Miller, C.S. Ejsing, F. Fröhlich. Writing—original draft:: S. Limar, F. Fröhlich. Writing—review and editing: All authors.

Disclosures: The authors declare no competing interests exist.

Submitted: 30 September 2021

Revised: 21 October 2022

Accepted: 3 February 2023

References

Alessenko, A.V. and E. Albi. 2020. Exploring sphingolipid implications in neurodegeneration. *Front. Neurol.* 11:437. <https://doi.org/10.3389/fneur.2020.00437>

Andrieu-Abadie, N., and T. Levade. 2002. Sphingomyelin hydrolysis during apoptosis. *Biochim. Biophys. Acta.* 1585:126–134. [https://doi.org/10.1016/S1388-1981\(02\)00332-3](https://doi.org/10.1016/S1388-1981(02)00332-3)

Antonny, B., J. Bigay, and B. Mesmin. 2018. The oxysterol-binding protein cycle: Burning off PI(4)P to transport cholesterol. *Annu. Rev. Biochem.* 87:809–837. <https://doi.org/10.1146/annurev-biochem-061516-044924>

Barlowe, C., and R. Schekman. 1993. SEC12 encodes a guanine-nucleotide-exchange factor essential for transport vesicle budding from the ER. *Nature.* 365:347–349. <https://doi.org/10.1038/365347a0>

Behnia, R., F.A. Barr, J.J. Flanagan, C. Barlowe, and S. Munro. 2007. The yeast orthologue of GRASP65 forms a complex with a coiled-coil protein that contributes to ER to Golgi traffic. *J. Cell Biol.* 176:255–261. <https://doi.org/10.1083/jcb.200607151>

Bisinski, D.D., I. Gomes Castro, M. Mari, S. Walter, F. Fröhlich, M. Schuldiner, and A. González Montoro. 2022. Cvm1 is a component of multiple vacuolar contact sites required for sphingolipid homeostasis. *J. Cell Biol.* 221:e202103048. <https://doi.org/10.1083/jcb.202103048>

Bourbon, N.A., L. Sandirasegarane, and M. Kester. 2002. Ceramide-induced inhibition of Akt is mediated through protein kinase zeta: Implications for growth arrest. *J. Biol. Chem.* 277:3286–3292. <https://doi.org/10.1074/jbc.M110541200>

Brace, J.L., R.L. Lester, R.C. Dickson, and C.M. Rudin. 2007. SVF1 regulates cell survival by affecting sphingolipid metabolism in *Saccharomyces cerevisiae*. *Genetics.* 175:65–76. <https://doi.org/10.1534/genetics.106.064527>

Cornell, R.B., and S.G. Taneva. 2006. Amphipathic helices as mediators of the membrane interaction of amphitropic proteins, and as modulators of bilayer physical properties. *Curr. Protein Pept. Sci.* 7:539–552. <https://doi.org/10.2174/138920306779025675>

Cox, J., and M. Mann. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26:1367–1372. <https://doi.org/10.1038/nbt.1511>

Cox, J., N. Neuhauser, A. Michalski, R.A. Scheltema, J.V. Olsen, and M. Mann. 2011. Andromeda: A peptide search engine integrated into the MaxQuant environment. *J. Proteome Res.* 10:1794–1805. <https://doi.org/10.1021/pr101065j>

de Saint-Jean, M., V. Delfosse, D. Douguet, G. Chicanne, B. Payrastre, W. Bourguet, B. Antonny, and G. Drin. 2011. Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers. *J. Cell Biol.* 195:965–978. <https://doi.org/10.1083/jcb.201104062>

Dickson, R.C., and R.L. Lester. 1999. Yeast sphingolipids. *Biochim. Biophys. Acta.* 1426:347–357. [https://doi.org/10.1016/S0304-4165\(98\)00135-4](https://doi.org/10.1016/S0304-4165(98)00135-4)

Dobrowsky, R.T., C. Kamibayashi, M.C. Mumby, and Y.A. Hannun. 1993. Ceramide activates heterotrimeric protein phosphatase 2A. *J. Biol. Chem.* 268:15523–15530. [https://doi.org/10.1016/S0021-9258\(18\)82288-8](https://doi.org/10.1016/S0021-9258(18)82288-8)

Doering, T.L., and R. Schekman. 1997. Glycosyl-phosphatidylinositol anchor attachment in a yeast in vitro system. *Biochem. J.* 328:669–675. <https://doi.org/10.1042/bj3280669>

Drin, G., and B. Antonny. 2010. Amphipathic helices and membrane curvature. *FEBS Lett.* 584:1840–1847. <https://doi.org/10.1016/j.febslet.2009.10.022>

Eberhardt, J., D. Santos-Martins, A.F. Tillack, and S. Forli. 2021. AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. *J. Chem. Inf. Model.* 61:3891–3898. <https://doi.org/10.1021/acs.jcim.1c00203>

Eisenberg, T., and S. Büttner. 2014. Lipids and cell death in yeast. *FEMS Yeast Res.* 14:179–197. <https://doi.org/10.1111/1567-1364.12105>

Eising, S., L. Thiele, and F. Fröhlich. 2019. A systematic approach to identify recycling endocytic cargo depending on the GARP complex. *Elife.* 8:e42837. <https://doi.org/10.7554/eLife.42837>

Ejsing, C.S., J.L. Sampaio, V. Surendranath, E. Duchoslav, K. Ekroos, R.W. Klemm, K. Simons, and A. Shevchenko. 2009. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. *Proc. Natl. Acad. Sci. USA.* 106:2136–2141. <https://doi.org/10.1073/pnas.0811700106>

Ellis, S.R., M.R.L. Paine, G.B. Eijkel, J.K. Pauling, P. Husen, M.W. Jervelund, M. Hermansson, C.S. Ejsing, and R.M.A. Heeren. 2018. Automated, parallel mass spectrometry imaging and structural identification of lipids. *Nat. Methods.* 15:515–518. <https://doi.org/10.1038/s41592-018-0010-6>

Encinar Del Dedo, J., I.M. Fernández-Golbano, L. Pastor, P. Meler, C. Ferrer-Orta, E. Rebollo, and M.I. Geli. 2021. Coupled sterol synthesis and transport machineries at ER-endocytic contact sites. *J. Cell Biol.* 220:e20210016. <https://doi.org/10.1083/jcb.202010016>

Esch, B.M., S. Limar, A. Bogdanowski, C. Gournas, T. More, C. Sundag, S. Walter, J.J. Heinisch, C.S. Ejsing, B. André, and F. Fröhlich. 2020. Uptake of exogenous serine is important to maintain sphingolipid homeostasis in *Saccharomyces cerevisiae*. *PLoS Genet.* 16:e1008745. <https://doi.org/10.1371/journal.pgen.1008745>

Flower, D.R. 1996. The lipocalin protein family: Structure and function. *Biochem. J.* 318:1–14. <https://doi.org/10.1042/bj3180001>

Fröhlich, F., R. Christiano, and T.C. Walther. 2013. Native SILAC: Metabolic labeling of proteins in prototroph microorganisms based on lysine synthesis regulation. *Mol. Cell. Proteomics.* 12:1995–2005. <https://doi.org/10.1074/mcp.M112.025742>

Funato, K., and H. Riezman. 2001. Vesicular and nonvesicular transport of ceramide from ER to the Golgi apparatus in yeast. *J. Cell Biol.* 155:949–959. <https://doi.org/10.1083/jcb.200105033>

Gao, J., F. Reggiori, and C. Ungermann. 2018. A novel in vitro assay reveals SNARE topology and the role of Ykt6 in autophagosome fusion with vacuoles. *J. Cell Biol.* 217:3670–3682. <https://doi.org/10.1083/jcb.201804039>

Gautier, R., D. Douguet, B. Antonny, and G. Drin. 2008. HELIQUEST: A web server to screen sequences with specific α -helical properties. *Bioinformatics.* 24:2101–2102. <https://doi.org/10.1093/bioinformatics/btn392>

- Pauling, J.K., M. Hermansson, J. Hartler, K. Christiansen, S.F. Gallego, B. Peng, R. Ahrends, and C.S. Ejsing. 2017. Proposal for a common nomenclature for fragment ions in mass spectra of lipids. *PLoS One*. 12: e0188394. <https://doi.org/10.1371/journal.pone.0188394>
- Peng, B., D. Kopczyński, B.S. Pratt, C.S. Ejsing, B. Burla, M. Hermansson, P.I. Benke, S.H. Tan, M.Y. Chan, F. Torta, et al. 2020. LipidCreator workbench to probe the lipidomic landscape. *Nat. Commun.* 11:1–14. <https://doi.org/10.1038/s41467-020-15960-z>
- Perez-Riverol, Y., J. Bai, C. Bandla, D. García-Seisdedos, S. Hewapathirana, S. Kamatchinathan, D.J. Kundu, A. Prakash, A. Frericks-Zipper, M. Eisenacher, et al. 2022. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res.* 50: D543–D552. <https://doi.org/10.1093/nar/gkab1038>
- Pickersgill, L., G.J. Litherland, A.S. Greenberg, M. Walker, and S.J. Yeaman. 2007. Key role for ceramides in mediating insulin resistance in human muscle cells. *J. Biol. Chem.* 282:12583–12589. <https://doi.org/10.1074/jbc.M611157200>
- Pino, L.K., B.C. Searle, J.G. Bollinger, B. Nunn, B. MacLean, and M.J. MacCoss. 2020. The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. *Mass Spectrom. Rev.* 39:229–244. <https://doi.org/10.1002/mas.21540>
- Poon, P.P., D. Cassel, A. Spang, M. Rotman, E. Pick, R.A. Singer, and G.C. Johnston. 1999. Retrograde transport from the yeast Golgi is mediated by two ARF GAP proteins with overlapping function. *EMBO J.* 18: 555–564. <https://doi.org/10.1093/emboj/18.3.555>
- Roelants, F.M., D.K. Breslow, A. Muir, J.S. Weissman, and J. Thorner. 2011. Protein kinase Ypk1 phosphorylates regulatory proteins Orm1 and Orm2 to control sphingolipid homeostasis in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA.* 108:19222–19227. <https://doi.org/10.1073/pnas.1116948108>
- Sandager, L., M.H. Gustavsson, U. Ståhl, A. Dahlqvist, E. Wiberg, A. Banas, M. Lenman, H. Ronne, and S. Stymne. 2002. Storage lipid synthesis is non-essential in yeast. *J. Biol. Chem.* 277:6478–6482. <https://doi.org/10.1074/jbc.M109109200>
- Sarmientos, F., G. Schwarzmann, K. Sandhoff, and F.S. Furbish. 1986. Specificity of human glucosylceramide β -glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system. *Eur. J. Biochem.* 160:527–535. <https://doi.org/10.1111/j.1432-1033.1986.tb10071.x>
- Sawai, H., Y. Okamoto, C. Luberto, C. Mao, A. Bielawska, N. Domae, and Y.A. Hannun. 2000. Identification of ISC1 (YER019w) as inositol phosphosphingolipid phospholipase C in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 275:39793–39798. <https://doi.org/10.1074/jbc.M007721200>
- Schmidt, O., Y. Weyer, V. Baumann, M.A. Widerin, S. Eising, M. Angelova, A. Schleiffer, L. Kremser, H. Lindner, M. Peter, et al. 2019. Endosome and Golgi-associated degradation (EGAD) of membrane proteins regulates sphingolipid metabolism. *EMBO J.* 38:e101433. <https://doi.org/10.15252/embj.2018101433>
- Senkal, C.E., M.F. Salama, A.J. Snider, J.J. Allopenna, N.A. Rana, A. Koller, Y.A. Hannun, and L.M. Obeid. 2017. Ceramide is metabolized to acylceramide and stored in lipid droplets. *Cell Metab.* 25:686–697. <https://doi.org/10.1016/j.cmet.2017.02.010>
- Shimobayashi, M., W. Oppliger, S. Moes, P. Jenö, and M.N. Hall. 2013. TORC1-regulated protein kinase Npr1 phosphorylates Orm to stimulate complex sphingolipid synthesis. *Mol. Biol. Cell.* 24:870–881. <https://doi.org/10.1091/mbc.e12-10-0753>
- Smathers, R.L., and D.R. Petersen. 2011. The human fatty acid-binding protein family: Evolutionary divergences and functions. *Hum. Genomics.* 5: 170–191. <https://doi.org/10.1186/1479-7364-5-3-170>
- Stefan, C.J., A.G. Manford, D. Baird, J. Yamada-Hanff, Y. Mao, and S.D. Emr. 2011. Osh proteins regulate phosphoinositide metabolism at ER-plasma membrane contact sites. *Cell.* 144:389–401. <https://doi.org/10.1016/j.cell.2010.12.034>
- Teixeira, V., T.C. Medeiros, R. Vilaça, A.T. Pereira, S.R. Chaves, M. Côrte-Real, P. Moradas-Ferreira, and V. Costa. 2015. Ceramide signalling impinges on Sit4p and Hog1p to promote mitochondrial fission and mitophagy in Isclp-deficient cells. *Cell. Signal.* 27:1840–1849. <https://doi.org/10.1016/j.cellsig.2015.06.001>
- Trott, O., and A.J. Olson. 2009. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* 31:455–461. <https://doi.org/10.1002/jcc.21334>
- Vacaru, A.M., F.G. Tafesse, P. Ternes, V. Kondylis, M. Hermansson, J.F.H.M. Brouwers, P. Somerharju, C. Rabouille, and J.C.M. Holthuis. 2009. Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER. *J. Cell Biol.* 185:1013–1027. <https://doi.org/10.1083/jcb.200903152>
- Varadi, M., S. Anyango, M. Deshpande, S. Nair, C. Natassia, G. Yordanova, D. Yuan, O. Stroe, G. Wood, A. Laydon, et al. 2022. AlphaFold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res.* 50:D439–D444. <https://doi.org/10.1093/nar/gkab1061>
- Voynova, N.S., C. Vionnet, C.S. Ejsing, and A. Conzelmann. 2012. A novel pathway of ceramide metabolism in *Saccharomyces cerevisiae*. *Biochem. J.* 447:103–114. <https://doi.org/10.1042/BJ20120712>
- Walther, T.C., and M. Mann. 2010. Mass spectrometry-based proteomics in cell biology. *J. Cell Biol.* 190:491–500. <https://doi.org/10.1083/jcb.201004052>
- Weekes, D., S.S. Krishna, C. Bakolitsa, I.A. Wilson, A. Godzik, and J. Wooley. 2010. TOPSAN: A collaborative annotation environment for structural genomics. *BMC Bioinformatics.* 11:426. <https://doi.org/10.1186/1471-2105-11-426>
- Wong, L.H., A.T. Gatta, and T.P. Levine. 2018. Lipid transfer proteins: The lipid commute via shuttles, bridges and tubes. *Nat. Rev. Mol. Cell Biol.* 20:85–101. <https://doi.org/10.1038/s41580-018-0071-5>
- Wuestehube, L.J., and R.W. Schekman. 1992. Reconstitution of transport from endoplasmic reticulum to Golgi complex using endoplasmic reticulum-enriched membrane fraction from yeast. *Methods Enzymol.* 219:124–136. [https://doi.org/10.1016/0076-6879\(92\)19015-X](https://doi.org/10.1016/0076-6879(92)19015-X)

Supplemental material




Figure S1. **Analysis of SVF1 genetic interactions with other potential ceramide transfer protein.** (a) Quantification of tetrad analysis. Relative colony sizes of tetrads of diploid *osh2Δosh3Δosh4Δsvf1Δ* cells shown as fold change from WT tetrads. Error bars represent standard deviations. (b) Quantification of tetrad analysis. Relative colony sizes of tetrads of diploid *osh2Δosh3Δosh4Δnvj2Δ* shown as fold change from WT tetrads. Error bars represent standard deviations. (c) Tetrad analysis of *svf1Δ* (green) mutants crossed with *sur2Δ* (red). (d) Tetrad analysis of diploid *svf1Δydr222wΔylr225cΔsur2Δ* cells. *svf1Δ* (green); *ydr222wΔ* (blue); *ylr225cΔ* (yellow); *sur2Δ* (red). (e) Helical wheel representation of the first 18 amino acids of Svf1. The projection was generated by the Heliquest software (<http://heliquest.ipmc.cnrs.fr>). (f) Helical wheel representation of the first 18 amino acids of Ydr222w. (g) Helical wheel representation of the first 18 amino acids of Ylr225c.




Figure S2. **Tetrad dissections of N- and C-terminal tagged SVF1.** (a) Tetrad analysis of a marker less generated GFP-Svf1 strain crossed with *sur2Δ*. Tetrads are numbered 1–5. Spores of the tetrads are labeled A to D. (b) Tetrad analysis of a Svf1-GFP strain crossed with *sur2Δ*. Tetrads are numbered 1–5. Spores of the tetrads are labeled A to D.




Figure S3. **Expression levels of plasmid expressed Svf1 are slightly altered.** (a) Expression levels of Svf1-GFP constructs used in this study. Equal amounts of cells were lysed and analyzed by Western blotting using antibodies against the GFP-tag or Pgk1 as a loading control. NC = negative control/ WT strain; end. WT = Svf1 GFP tagged endogenously with GFP; pl. WT = Svf1-GFP expressed under its endogenous promoter from an integrative plasmid; V12D = Svf1_{V12D}-GFP expressed under its endogenous promoter from an integrative plasmid; G7A/G8A = Svf1_{G7A/G8A}-GFP expressed under its endogenous promoter from an integrative plasmid; L2E = Svf1_{L2E}-GFP expressed under its endogenous promoter from an integrative plasmid. (b) Helical wheel representation of the first 18 amino acids with the hydrophobic amino acids shown in yellow and the hydrophobic moment shown by the arrow and expressed in μH above the arrow for the L2E mutant with the exchange of the hydrophobic leucine to the charged glutamate (red). Source data are available for this figure: SourceData FS3.

Downloaded from http://upress.org/jcb/article-pdf/222/5/e202109162/1449092/jcb_2021_09162.pdf by guest on 05 December 2023




Figure S4. **Analysis of Sv1 acetylation and analyses of Sv1 mutants.** (a) Mass spectrometric analysis of the N-terminus of Sv1 showing that it is N-terminally acetylated. MS/MS spectrum extracted from MaxQuant data from a GFP pulldown of Sv1. Detected y-ions are labeled in red, b-ions are labeled in blue. The sequence showing all identified y- and b-ions is shown in the top right position. (b) Tetrad analysis of the *svf1Δpl.Grh1_{1-18aa}Svf1_{19-481aa}-GFP* (blue and green, respectively) mutants crossed with *sur2Δ* (red). (c) Evaluation of the binding of the AHs from WT, V12D mutant, and G7A/G8A mutant to the ER expressed as cytosol/ER ratio in %. Intensities of the GFP signal measured in cytosolic areas were divided by the intensities of the GFP signal at the ER measured in 0.065 μm^2 . The signal of Sec63-Halo was used to differentiate between Cytosol and ER areas. $n \leq 48$.

Downloaded from http://jcb.org/jcb/article-pdf/222/5/e202109162/1449092/jcb_2021_09162.pdf by guest on 05 December 2023




Figure S5. **In vitro COP-II budding assays for lipidomic analysis.** **(a)** Experimental setup of COPII budding assays. **(b)** Western blot analysis of COPII budding assays using antibodies against Sec22 (upper panels), Erv46 (middle panels), and GFP tagged Svf1 variants (lower panels). **(c)** Mass spectrometric analysis of ceramides from in vitro budded COP-II vesicles. The percentage of ceramide detected in the COPII vesicle fraction versus the sum of ceramides detected in both pelleted membranes and COPII vesicles is shown for WT Svf1 (black) and Svf1_{V12D} (gray) for experiments with COPII coat added and without COPII coat added (*n* = 3). **(d)** Western blot analysis of Gas1 in WT, *svf1Δ*, and *emp24Δ* cells. Only in *emp24Δ* the pre-form of Gas1 is detected. Source data are available for this figure: SourceData F55.




Figure S6. **Model for sphingolipid metabolism and Svf1 co-localization with the IPC synthase.** (a) Overview of the multi-pathway flux analysis. $^{13}\text{C}_3$ - ^{15}N -serine and $^2\text{H}_6$ -inositol were added as tracers to exponentially growing cells. The potential incorporation into SP metabolites are shown in a simplified model of yeast SP metabolism. KDHS, 3-ketodihydrospingosine; DHS, dihydrospingosine; PHS, phytosphingosine; PI, phosphatidylinositol; IPC, inositol phosphorylceramide; MIPC, mannosylinositol phosphorylceramide; $\text{M}(\text{IP})_2\text{C}$, mannosyl-diinositol phosphorylceramide as well as in phosphatidylinositol and phosphatidylserine. (b) Svf1-GFP (green) was expressed in cells expressing Mnn9-mKate (cis-Golgi, red) and Aur1-Halo (mid-Golgi, blue). Scale bar = 5 μM . (c) Quantification of Svf1 dots co-localizing with Mnn9, Aur1, Mnn9, and Aur1, only Mnn9, and only Aur1. ($n = 100$ Svf1 dots, triplicates).




Figure S7. **Purification of Svfl from yeast cells.** (a) Svfl-FLAG overproduced from the GAL1 promoter was purified via FLAG tag and analyzed by SDS-PAGE. I, Input; FT, flow through; W1, wash 1; W2, wash 2; E1, eluate 1; E2, eluate 2; B, beads. (b) Svfl_{V12D}-FLAG overproduced from the GAL1 promoter was purified via FLAG tag and analyzed by SDS-PAGE. I, Input; FT, flow through; W1, wash 1; W2, wash 2; E1, eluate 1; E2, eluate 2; B, beads. (c) Svfl_{G7A/G8A}-FLAG overproduced from the GAL1 promoter was purified via FLAG tag and analyzed by SDS-PAGE. I, Input; FT, flow through; W1, wash 1; W2, wash 2; E1, eluate 1; E2, eluate 2; B, beads. (d) Svfl_{H273A/H274A}-FLAG overproduced from the GAL1 promoter was purified via FLAG tag and analyzed by SDS-PAGE. I, Input; FT, flow through; W1, wash 1; E1, eluate 1. (e) Mass photometry analysis of the purified proteins from a–d. Source data are available for this figure: SourceData FS7.

Video 1. **Representative midsection time lapse fluorescence microscopy of yeast cells expressing Svf1-GFP and Mnn9-mCherry.** Images were recorded with 0.9 s intervals.

Provided online are Table S1, Table S2, and Table S3. Table S1 lists all proteins identified including SILAC ratios and intensities from the GFP pulldowns of labeled Svf1-GFP cells compared to unlabeled WT shown in Fig. 5 a. Table S2 lists all yeast strains used in this study. Table S3 lists all plasmids used in this study.